

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number  
WO 01/47543 A2(51) International Patent Classification<sup>7</sup>: A61K 38/16,  
48/00, C07K 14/00, C12N 15/62, A61P 37/00, 37/04,  
37/06, 37/08Marc [AU/GB]; Kennedy Institute of Rheumatology Division,  
Imperial College School of Medicine, 1 Aspenlea Road,  
Hammersmith, London W6 8LH (GB).

(21) International Application Number: PCT/GB00/04925

(74) Agent: MILES, John, S.; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD, United Kingdom (GB).

(22) International Filing Date:  
22 December 2000 (22.12.2000)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

## Published:

(30) Priority Data:  
9930616.9 24 December 1999 (24.12.1999) GB

— Without international search report and to be republished upon receipt of that report.

(71) Applicant (for all designated States except US): THE MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY TRUST [GB/GB]; 1 Aspenlea Road, Hammersmith, London W6 8LH (GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): FOXWELL, Brian [GB/GB]; Kennedy Institute of Rheumatology Division, Imperial College School of Medicine, 1 Aspenlea Road, Hammersmith, London W6 8LH (GB). FELDMANN,

[Continued on next page]

(54) Title: ACTIVATION AND INHIBITION OF THE IMMUNE SYSTEM



WO 01/47543 A2



Untreated

PSI(0.1 μM)  
treated(57) Abstract: Activation of the immune response by NF- $\kappa$ B inducers, induction of an anergic response by NF- $\kappa$ B inhibitors and the inhibition and activation of immune response by the administration of an activator or inhibitor of NF- $\kappa$ B is disclosed. Examples of NF- $\kappa$ B inhibitors include I $\kappa$ B $\alpha$ , PSI, a nucleotide sequence encoding I $\kappa$ B $\alpha$  anti-sense nucleic acid encoding an NF- $\kappa$ B sequence, such as Rel B, and anti-NF- $\kappa$ B antibodies. Examples of NF- $\kappa$ B inducers include NIK, MEKK, IKK2, TFRRF2 and Rel B. Also disclosed are vectors encoding inducers and inhibitors of NF- $\kappa$ B, for example adenoviral vectors.

BEST AVAILABLE COPY



*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## ACTIVATION AND INHIBITION OF THE IMMUNE SYSTEM

The invention relates to the activation and inhibition of the immune system by using inducers and inhibitors of NF- $\kappa$ B, and to the use of such inducers and inhibitors to treat transplant rejection, autoimmune disease, allergy, infectious disease and cancer.

Antigen presentation is a critical step in the initiation of the immune response, and dendritic cells (DC) are acknowledged to be the most potent antigen presenting cells for naïve T cells. This is partly due to their high expression of MHC and costimulatory molecules (Hart (1997) *Blood* 90, 3245-3287). However, little is known about the biochemical pathways which regulate antigen presenting function, partly due to the difficulty in transfecting DC. Using an inhibitor of I $\kappa$ B degradation, PSI that produces an effective inhibition of NF- $\kappa$ B activation, the inventors show here abrogation of the capacity of DC to induce a mixed lymphocyte reaction. The mechanism suppressed DC function and diminished antigen presentation involved downregulation of multiple steps, including costimulatory molecules (CD86 and CD80), HLA class II (DQ>DR) as well as cytokines such as IL-12. Moreover, T cell exposed to such DC were unable to be stimulated by subsequent encounters with normal DC. These results point out NF- $\kappa$ B as an effective target for blocking antigen presentation.

Dendritic cells are of major importance in the presentation of antigen to naïve T cells in the primary immune response. They are bone marrow derived cells which were first described in the early 1970's by Steinman and Cohn (1973) *J. Exp. Med.* 179, 1109. Studies on dendritic cells were initially hampered by the difficulty in isolating them in sufficient numbers,

but this problem was overcome in part by the realisation that a subset of DC could be generated *in vitro* by culture of CD34+ cells or human monocytes with GM-CSF and IL-4. These cultured DC have the phenotype of immature DC, and can be matured into high MHC, high CD80/86 expressing cells through incubation with TNF $\alpha$  or LPS (Bender *et al* (1996) *J. Immunol. Methods* **196**, 121; Romani *et al* (1996) *J. Immunol. Methods* (1996) **196**, 137; Reddy *et al* (1997) *Blood* **90**, 3640).

DC can also be derived from a post colony-forming unit CD14+ intermediate in the peripheral blood. DC migrate to peripheral sites in skin, mucosa, spleen and thymus. They have been implicated in a variety of clinically important processes, including allograft rejection, atopic disorders, autoimmunity and anti-tumour immunity.

DC can be cultured *ex vivo* from CD34+ stem cells or CD14+ peripheral blood monocytes using cytokines, principally GM-CSF, IL-4 and TNF $\alpha$  (Scabols *et al* (1995) *J. Immunol.* **154**, 5651-5661). DC from both these sources are immunocompetent and can take up exogenously presented antigen, process it and then present it to cytotoxic T-cells (Grabbe *et al* (1995) *Immunology Today* **16**, 117-121; Girolomoni & Ricciardi-Castagnoli (1997) *Immunology Today* **18**, 102-104). DC can transfer antigen-specific tumour immunity generated *in vivo* (Kwak *et al* (1995) *Lancet* **345**, 1016-1020) and autologous DC pulsed with tumour antigen *ex vivo* can induce a measurable anti-tumour effect (Hsu *et al* (1996) *Nature Medicine* **2**, 52-58).

DC can be effectively pulsed using a crude tumour membrane lysate, purified peptides or peptide fragments. The *ex vivo* expansion of autologous dendritic cells from patients, loading with a peptide antigen and reinfusion as adoptive immunotherapy, is described in, for example, WO/00/26249.

The importance of antigen presentation in the generation of immune response was confirmed by demonstration that blocking antigen presentation downregulates immune responses and is useful in treating animal models of disease. Thus antibody to murine MHC class II has been used to treat experimental allergic encephalomyelitis (Smith *et al* (1994) *Immunology* 83, 1), and blocking the CD80/86 costimulatory molecules with antibodies or CTLA4-Ig fusion protein is beneficial in transplants or animal models of arthritis (Lu *et al* (1999) *Gene Ther.* 6, 554-563). This has led to a search of new ways of downregulating antigen presentation which may be useful in human diseases or in transplantation.

NF- $\kappa$ B has been speculated as being involved in the immune system. This is summarised in, for example, the paper by Baeuerle P.A. and Henkel T. (Annual Reviews in Immunology, 1994, Vol. 12, pages 141-179). However, no-one has shown that NF- $\kappa$ B is indeed crucial in the activation and inhibition of the immune system, as the effects of activating or inactivating NF- $\kappa$ B on antigen representing cells were not amenable to study previously. The inventors, for the first time, have demonstrated the key role of NF- $\kappa$ B in the immune response.

20

The activation of the transcription factor NF- $\kappa$ B like proteins results from post-translational modification permitting translocation of the preformed transcription factor from the cytoplasm to the nucleus. This translocation is controlled by the phosphorylation and degradation of an inhibitor protein called I $\kappa$ B, which forms a complex with NF- $\kappa$ B, and thereby holds it in the cytoplasm. Stimulation of the cell by appropriate signals leads to modification of I $\kappa$ B which in turn results in its dissociation and/or degradation from NF- $\kappa$ B.

Binding of the I $\kappa$ B protein to NF- $\kappa$ B masks the nuclear localisation signal (NLS) of NF- $\kappa$ B. Upon stimulation of the cell with specific agents, which depend on the cell type and stage of cell development, I $\kappa$ B is modified in a way that disables binding to NF- $\kappa$ B, leading to dissociation of NF- $\kappa$ B from I $\kappa$ B.

NF- $\kappa$ B is a heterodimeric protein consisting of a 50 kD subunit (p50) and a 65 kD subunit (p65). The cDNAs for p50 and p65 have been cloned and have been shown to be homologous over a region of 300 amino acids.

10

Recently an additional member of the NF- $\kappa$ B family, Rel B, has been cloned as an immediate early response gene from serum-stimulated fibroblasts.

15

Both p50 and p65 are capable of forming homodimers, although with different properties: whereas p50 homodimers have strong DNA binders affinity but cannot transactivate transcription, the p65 homodimers can only weakly bind to DNA but are capable of transactivation. P50 is synthesised as the amino-terminal part of the 110 kD precursor (p110), which has no DNA binding and dimerisation activity. The carboxyl-terminal part contains eight ankyrin repeats, a motif found in several proteins involved in cell cycle control and differentiation.

20

Five I $\kappa$ B family members have been identified: I $\kappa$ B $\alpha$ , I $\kappa$ B $\beta$ , p105/I $\kappa$ B $\gamma$ , p110/ I $\kappa$ B $\Delta$  and I $\kappa$ B $\epsilon$  (Baeuerle and Baltimore, Cell 1996, Vol. 87, pages 13-20). All I $\kappa$ B-like family members contain multiple ankyrin repeats, which are essential for inhibition of NE- $\kappa$ B activation.

The inventors have found that many of the key features of the inflammatory response in human macrophages and in the rheumatoid synovium were dependent on the transcription factor NF- $\kappa$ B. The inventors have studied the proteosome inhibitory drug PSI, which was initially described as an inhibitor of the chymotrypsin-like activity of the proteosome. It was found that the production of many proinflammatory mediators, such as TNF $\alpha$ , IL-6, IL-2 were dependent on NF- $\kappa$ B (inhibitible by AdyI $\kappa$ B $\alpha$  disclosed in PCT/GB98/02753) whereas the anti-inflammatory cytokines and mediators, namely IL-10, IL-1 receptor antagonist, IL-11 were not affected. This suggested to us that NF- $\kappa$ B segregated accurately between these two classes of mediators, and so raised the question, in view of the close relationship of the inflammatory and immune systems of what the role of NF- $\kappa$ B might be in the induction of immunity.

15 The inventors first investigated the effect of the proteosome inhibitory drug PSI, which does not require the use of gene therapy. This is known to inhibit I $\kappa$ B degradation and hence NF- $\kappa$ B activation on the immunostimulatory function of dendritic cells, which is the key early event on the generation of a primary immune response.

20 They report that PSI treatment of mature, monocyte derived DC inhibited their capacity to induce T cell proliferation in the mixed lymphocyte response. To elucidate the mechanism of this effect, cell surface analysis, cytokine assays and co-cultures were performed, which suggested that 25 blocking NF- $\kappa$ B permits immunosuppressive mechanisms to become operational in the interaction between the dendritic cells and the T cells.

Furthermore, the inventors have demonstrated that the changes result in an anergic response. That is, they result in the inability to produce an immune response, even after removal of the original inhibiting compound.

5 The inventors have also realised that NF- $\kappa$ B can also be used as a target to induce or modulate an immune response. This is unexpected, as it has been shown Feuillard *et al* (1996) *Eur. J Immunol* 26, 2547-2551; Granelli-Piperno *et al* (1995) *Proc Natl. Acad. Sci. USA* 92, 10944-10948 the NF- $\kappa$ B is already activated in DC, and hence further activation would not have  
10 been expected to be beneficial.

15 A first aspect of the invention provides a method of inhibiting antigen presentation or inducing an anergic response in a mammal, such as a human, comprising administering a pharmaceutically-effective dose of an intracellular inhibitor of APC, such as DC, function.

By "intracellular inhibitor of APC function" we include any suitable inhibitor of antigen presenting cell function. By "APC function" we include the ability to present antigen, the ability to express MHC Class II, the ability  
20 to express cell surface molecules such as costimulatory molecules including CD80 and CD86, the ability to produce cytokines and the ability to induce anergy rather than activation. Typically the inhibitor of APC function is an inhibitor of DC function. Preferably, the inhibitor is an inhibitor of intracellular signalling within the APC. By "intracellular signalling within  
25 the APC" we include communication between the membrane and the nucleus, signalling which controls gene expression (including expression of CD80 and CD86) and control of cytoskeletal organisation. Inhibition of intracellular signalling include, for example, an inhibitor of NF- $\kappa$ B as described in more detail below.

For the avoidance of doubt, cytokines and molecules containing CPG motifs are not intracellular inhibitors of APC function since they act extracellularly. Clearly, the inhibitors are ones that do not kill the cell.

5

A further aspect of the invention provides a method of inhibiting antigen presentation or inducing an anergic response in a mammal comprising administering a pharmaceutically-effective dose of an inhibitor of NF- $\kappa$ B.

10 By pharmaceutically-effective dose, we mean an amount sufficient to induce the desired response in a mammal. This amount can be determined by routine clinical and experimental trials known in the art.

By mammal, we mean any mammal but especially a human.

15

Anergy is a form of immunological tolerance in which lymphocytes, in this case T lymphocytes after exposure to antigen in an inappropriate setting become refractory to subsequent optional immunogenic stimulus, usually the immunogenic dose of antigen in the context of activated antigen presenting cells (see Roitt, I., Broskoff, J. and Male, D. (1998, 5th edition) Immunology, Mosby, London). Thus, the invention provides methods in which a tolerogenic response is induced in a mammal.

20 Antigen presentation describes the display of antigen as peptide fragments bound to MHC molecules on the surface of a cell; T cells recognise antigen only when it is presented in this way.

25 A further aspect of the invention provides a method of treating an allergy or an autoimmune disease comprising administering a pharmaceutically-

effective dose of an intracellular inhibitor of APC, such as DC, function to induce an anergic response in a mammal.

A further aspect of the invention provides a method of treating an allergy or  
5 an autoimmune disease comprising administering a pharmaceutically-effective amount of an inhibitor of NF- $\kappa$ B to induce an anergic response in a mammal. The autoimmune disease may be any autoimmune disease such as rheumatoid arthritis, type I diabetes, multiple sclerosis, Crohn's disease, Hashimoto's thyroiditis, coeliac disease, myasthenia gravis, pemphigus  
10 vulgaris, systemic lupus erythematosus and Graves disease.

Allergies which may be treatable by the method described herein include allergies to the following allergens: Fel d 1 (the feline skin and salivary gland allergen of the domestic cat *Felis domesticus* - the amino acid sequence of which is disclosed in WO 91/06571), Der p I, Der p II, Der fI or Der fII (the major protein allergens from the house dust mite *dermatophagoides* - amino acid sequences disclosed in WO 94/24281).

The invention is applicable substantially to any allergy, including those caused by allergens present in any of the following: grass, tree and weed (including ragweed) pollens; fungi and moulds; foods eg fish, shellfish, crab, lobster, peanuts, nuts, wheat gluten, eggs and milk; stinging insects eg bee, wasp and hornet and the chironomidae (non-biting midges); spiders and mites, including the house dust mite; allergens found in the dander, urine, saliva, blood or other bodily fluid of mammals such as cat, dog, cows, pigs, sheep, horse, rabbit, rat, guinea pig, mouse and gerbil; airborne particulates in general; latex; and protein detergent additives.

Allergies to proteins from the following insects may also be treated: housefly, fruit fly, sheep blow fly, screw worm fly, grain weevil, silkworm, honeybee, non-biting midge larvae, bee moth larvae, mealworm, cockroach and larvae of *Tenibrio molitor* beetle.

5

A further aspect of the invention provides a method of preventing transplant rejection in a mammal, such as a human, comprising administering a pharmaceutically-effective dose of an intracellular inhibitor of APC, such as DC, function to induce an anergic response in a mammal.

10

A further aspect of the invention provides a method of preventing transplant rejection comprising administering a pharmaceutically-effective amount of NF- $\kappa$ B inhibitor to induce an anergic response.

15

The invention further relates to inhibitor of APC function such as NF- $\kappa$ B inhibitors for use as a medicament, to induce an anergic response, to inhibit the rejection of transplanted tissue, or as anti-autoimmune disease agents or to treat allergy.

20

The invention also provides a NF- $\kappa$ B inhibitor for use in the manufacture of a medicament to treat transplant rejection, allergy or an auto-immune disease.

25

Preferably the NF- $\kappa$ B inhibitor is an inhibitor of proteolysis, for example a proteosome inhibitor. The inhibitor may be PSI, available from Calbiochem. This is known as an inhibitor of proteosomes (Traechner, *et al.*, EMBO J. (1994), Vol. 13, pages 5433-41; Griscavage, *et al.*, PNAS (1996), Vol. 93, pages 3308-12; Bondeson, *et al.*, J Immunol. (1999), Vol. 162, pages 2939-45). ALLN (Jobin, *et al.*, Hepatology (1998), Vol. 27,

pages 1285-95); Lactacystin (Delic, *et al.* (1998), Vol 77, pages 1103-07); MG-132 (Jobin, *et al.* Supra); C-LFF and Calpain Inhibitors (Neauparfant and Hiscott, Cytokine & Growth Factor Reviews (1996), Vol. 7 pages 175-190); or CVT-134 (Lum, *et al.*, Biochem. Pharmacol (1998), Vol. 55, pages 5 1391-97) may also be used as inhibitors.

Other inhibitors include: Caffeic acid phenethyl ester (Natarajan, *et al.*, PNAS (1992), Vol. 93 pages 9090-95); Pyrrolidine dithiocarbonate (Schreck, *et al.*, J. Exp. Med. (1992), Vol. 175, pages 1181-94); Lovastatin 10 (Guijarro, *et al.*, Nephrol Dial Transplant (1996), Vol. 11, pages 990-996); Aselastine HCL (Yoneda, Japan. J. Pharmacol. (1997), Vol. 73, pages 145-153); Tepaxalin (Kazmi, *et al.*, J Cell. Biochem. (1995), Vol. 57, pages 299-310); (-)-epi gallocatechin-3-gallate (Lin & Lin, Mol. Pharmacol. (1997), Vol. 52, pages 465-472); deoxyspergualin (Tapper, *et al.*, J 15 Immunol. (1995), Vol. 155, pages 2427-36); Phenyl-N-tert-butylnitronone (Kotake, *et al.*, Biochem. Biophys Acta (1998), Vol. 1446, pages 77-84; Quercutin (Sato, *et al.*, J Rheumatol. (1997), Vol 24, pages 1680-84); Cucumin (Chan, Biochem, Pharmacol. (1998), Vol. 55, pages 965-973); or E3330 (Goto, *et al.*, Mol. Pharmacol (1996), Vol. 49, pages 860-873).

20

As is clear from the examples of NF- $\kappa$ B inhibitors and activators indicated herein, it is preferred that the inhibitor or activator enters the cell and acts within the cell, ie acts as an intracellular NF- $\kappa$ B inhibitor or activator, for example an intracellular modulator of intracellular signalling events leading 25 to NF- $\kappa$ B inhibition or activation.

In another embodiment of the invention, NF- $\kappa$ B may be inhibited by inhibitors of NF- $\kappa$ B, ie that act directly on the level (quantity), cellular location or activity of NF- $\kappa$ B. For example, the inhibitor may be a naturally

occurring regulator of NF- $\kappa$ B that interacts directly with NF- $\kappa$ B, such as an I $\kappa$ B.

5 Preferably the inhibitor is an I $\kappa$ B, especially I $\kappa$ B $\alpha$  is described in, for example, paper by Makarov, Gene Therapy, 1997, Vol. 4, pages 846-852, and in PCT/GB98/02753. Other inhibitors of NF- $\kappa$ B include antisense cDNA or oligonucleotides encoding for any of the known NF- $\kappa$ B subunits, e.g. p50, p65, Rel B. Bondeson *et al* (1999) *Proc. Natl. Acad. Sci. USA* 96, 5668 describes an I $\kappa$ B-encoding adenovirus.

10

The inhibitor may also be a ribozyme which selectively destroy mRNA encoding NF- $\kappa$ B, or an antisense molecule which prevents transcription of NF- $\kappa$ B or an antibody or antibody - like molecule which blocks NF- $\kappa$ B action. These inhibitors are described in more detail below. It will be 15 appreciated that inhibitors of APC, such as DC function, may also comprise ribozymes or antisense molecules or antibodies or antibody-like molecules which, for example, inhibit intracellular signalling within the APC.

20 It will be appreciated that inhibitors of inhibitors of NF- $\kappa$ B may act as inducers of NF- $\kappa$ B. Thus, antibodies or antisense molecules or ribozymes that block I $\kappa$ B $\alpha$  function or expression may act as inducers of NF- $\kappa$ B. The utility of such inducers is described below.

25 Ribozymes which may be encoded in the genomes of the viruses or virus-like particles herein disclosed are described in Cech and Herschlag "Site-specific cleavage of single stranded DNA" US 5,180,818; Altman *et al* "Cleavage of targeted RNA by RNase P" US 5,168,053, Cantin *et al* "Ribozyme cleavage of HIV-1 RNA" US 5,149,796; Cech *et al* "RNA

ribozyme restriction endoribonucleases and methods", US 5,116,742; Been *et al* "RNA ribozyme polymerases, dephosphorylases, restriction endonucleases and methods", US 5,093,246; and Been *et al* "RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods; cleaves single-stranded RNA at specific site by transesterification", US 4,987,071, all incorporated herein by reference.

Preferably the inhibitor is encoded by a nucleic acid sequence, for example within a vector, such as an adenovirus. The nucleic acid sequence encoding the inhibitor is preferably operatively linked to regulatory elements necessary for expression of said sequence. Such vectors may be used for gene therapy to enable the nucleic acid sequence encoding the inhibitor to be inserted into the body of a mammal. Methods of gene therapy, such as by using an adenovirus, are known in the art. The vector may also comprise a nucleic acid sequence encoding an antigenic molecule.

Preferably the vector construct used is AdvIkBa, disclosed in PCT/GB98/02753.

"Operatively linked" refers to juxtaposition such that the normal function of the components can be performed. Thus, a coding sequence "operatively linked" to regulatory elements refers to a configuration wherein the nucleic acid sequence encoding the inhibitor (or inducer, which is useful as described in more detail below), of NF- $\kappa$ B can be expressed under the control of the regulatory sequences.

"Regulatory sequences" refers to nucleic acid sequences necessary for the expression of an operatively linked coding sequence in a particular host

organism. For example, the regulatory sequences which are suitable for eukaryotic cells are promotors, polyadenylation signals, and enhancers.

“Vectors” means a DNA molecule comprising a single strand, double strand, circular or supercoiled DNA. Suitable vectors include retroviruses, adenoviruses, adeno-associated viruses, pox viruses and bacterial plasmids. Retroviral vectors are retroviruses that replicate by randomly integrating their genome into that of the host. Suitable retroviral vectors are described in WO 92/07573.

10

Adenovirus is a linear double-standard DNA Virus. Suitable adenoviral vectors are described in Rosenfeld et al, Science, 1991, Vol. 252, page 432.

15 Adeno-associated viruses (AAV) belong to the parvo virus family and consist of a single strand DNA or about 4-6 KB.

20 Pox viral vectors are large viruses and have several sites in which genes can be inserted. They are thermostable and can be stored at room temperature. Safety studies indicate that pox viral vectors are replication-defective and cannot be transmitted from host to host or to the environment.

25 Vectors comprising nucleic acid encoding an NF- $\kappa$ B inhibitor (or inducer, as described below) may be introduced into a mammal in the form of liposomes in a manner known in the art. Alternatively, liposomes may be used in the form of aerosols in order to access the body by means of the mucus membrane or lung. Such techniques are known in the art.

Immunoliposomes (antibody-directed liposomes) are especially useful in targeting to cell types which over-express a cell surface protein for which

antibodies are available, as is possible with dendritic cells or precursors, for example using antibodies to CD1, CD14 or CD83 (or other dendritic cell or precursor cell surface molecule, as indicated above). For the preparation of immuno-liposomes MPB-PE (N-[4-(p-maleimidophenyl)butyryl]-  
5 phosphatidylethanolamine) is synthesised according to the method of Martin & Papahadjopoulos (1982) *J. Biol. Chem.* **257**, 286-288. MPB-PE is incorporated into the liposomal bilayers to allow a covalent coupling of the antibody, or fragment thereof, to the liposomal surface. The liposome is conveniently loaded with the DNA or other genetic construct of the  
10 invention for delivery to the target cells, for example, by forming the said liposomes in a solution of the DNA or other genetic construct, followed by sequential extrusion through polycarbonate membrane filters with 0.6 µm and 0.2 µm pore size under nitrogen pressures up to 0.8 MPa. After extrusion, entrapped DNA construct is separated from free DNA construct  
15 by ultracentrifugation at 80 000 x g for 45 min. Freshly prepared MPB-PE-liposomes in deoxygenated buffer are mixed with freshly prepared antibody (or fragment thereof) and the coupling reactions are carried out in a nitrogen atmosphere at 4°C under constant end over end rotation overnight. The immunoliposomes are separated from unconjugated antibodies by  
20 ultracentrifugation at 80 000 x g for 45 min. Immunoliposomes may be injected, for example intraperitoneally or directly into a site where the target cells are present, for example subcutaneously. Naked DNA encoding an inhibitor of NF-κB, in the form of a DNA vaccine, may also be used as an inhibitor of NF-κB.

25

As noted above, an alternative inhibitor is the use of anti-sense nucleic acid to an NF-κB sequence, for example Rel B. Such an anti-sense nucleic acid comprises a nucleic acid sequence which is capable of binding to an NF-κB

nucleic acid sequence, inhibiting transcription of the NF- $\kappa$ B sequence. Methods of producing anti-sense nucleic acid *per se* are known in the art.

Antisense oligonucleotides are single-stranded nucleic acids, which can 5 specifically bind to a complementary nucleic acid sequence. By binding to the appropriate target sequence, an RNA-RNA, a DNA-DNA, or RNA-DNA duplex is formed. These nucleic acids are often termed "antisense" because they are complementary to the sense or coding strand of the gene. Recently, formation of a triple helix has proven possible where the 10 oligonucleotide is bound to a DNA duplex. It was found that oligonucleotides could recognise sequences in the major groove of the DNA double helix. A triple helix was formed thereby. This suggests that it is possible to synthesise a sequence-specific molecules which specifically bind double-stranded DNA *via* recognition of major groove hydrogen binding 15 sites.

By binding to the target nucleic acid, the above oligonucleotides can inhibit 20 the function of the target nucleic acid. This could, for example, be a result of blocking the transcription, processing, poly(A)addition, replication, translation, or promoting inhibitory mechanisms of the cells, such as promoting RNA degradations.

Antisense oligonucleotides are prepared in the laboratory and then 25 introduced into cells, for example by microinjection or uptake from the cell culture medium into the cells, or they are expressed in cells after transfection with plasmids or retroviruses or other vectors carrying an antisense gene. Antisense oligonucleotides were first discovered to inhibit viral replication or expression in cell culture for Rous sarcoma virus, vesicular stomatitis virus, herpes simplex virus type 1, simian virus and

influenza virus. Since then, inhibition of mRNA translation by antisense oligonucleotides has been studied extensively in cell-free systems including rabbit reticulocyte lysates and wheat germ extracts. Inhibition of viral function by antisense oligonucleotides has been demonstrated *in vitro* using 5 oligonucleotides which were complementary to the AIDS HIV retrovirus RNA (Goodchild, J. 1988 "Inhibition of Human Immunodeficiency Virus Replication by Antisense Oligodeoxynucleotides", *Proc. Natl. Acad. Sci. (USA)* 85(15), 5507-11). The Goodchild study showed that oligonucleotides that were most effective were complementary to the 10 poly(A) signal; also effective were those targeted at the 5' end of the RNA, particularly the cap and 5' untranslated region, next to the primer binding site and at the primer binding site. The cap, 5' untranslated region, and poly(A) signal lie within the sequence repeated at the ends of retrovirus RNA (R region) and the oligonucleotides complementary to these may bind 15 twice to the RNA.

Typically, antisense oligonucleotides are 15 to 35 bases in length. For example, 20-mer oligonucleotides have been shown to inhibit the expression of the epidermal growth factor receptor mRNA (Witters *et al*, 20 *Breast Cancer Res Treat* 53:41-50 (1999)) and 25-mer oligonucleotides have been shown to decrease the expression of adrenocorticotropic hormone by greater than 90% (Frankel *et al*, *J Neurosurg* 91:261-7 (1999)). However, it is appreciated that it may be desirable to use oligonucleotides with lengths outside this range, for example 10, 11, 12, 13, or 14 bases, or 25 36, 37, 38, 39 or 40 bases.

The anti-sense nucleic acid may be encoded by a suitable vector, for example of the type discussed above.

The inhibitor may alternatively be an anti-NF- $\kappa$ B vaccine or an antibody against NF- $\kappa$ B or fragment thereof such as an Fv. The vaccine or antibody may be against any suitable part of NF- $\kappa$ B providing it results in the inhibition of NF- $\kappa$ B. Preferably the antibody is a monoclonal antibody.

5 Methods of producing vaccines and antibodies are known in the art. Alternatively, the antibody may be a suitable antibody fragment, such as an Fab or (Fab)<sub>2</sub> fragment or Fv, which still retains its anti-NF- $\kappa$ B activity. The antibody may be linked to polypeptide sequences that permit entry into cells, ie, the antibody (particularly antibody fragment) may be joined to a 10 moiety that facilitates uptake of the antibody by a cell, for example a DC. For example, the antibody may be linked to a lipophilic molecule or polypeptide domain that is capable of promoting cellular uptake of the molecule or the interacting polypeptide, as known to those skilled in the art. Thus, the moiety may derivable from the *Antennapedia* helix 3 (Derossi *et* 15 *al* (1998) *Trends Cell Biol* 8, 84-87), or from sequences of HIV, generally tat, that permit entry into cells. Such sequences are known and include the penetration peptide and the sequences of HIV generally engineered tat that permit entry into cells. Alternatively, the cDNA encoding such antibodies (preferably antibody fragments) could be delivered as a vector as described 20 above.

A further aspect of the invention provides a method of stimulating antigen presentation or of stimulating an immune response in a mammal, such as a human, comprising administering a pharmaceutically effective amount of an 25 intracellular inducer of APC, such as DC, function.

By "intracellular enhancer of APC function" we include any suitable enhancer of antigen presenting cell function. Typically, the enhancer is an

enhancer of DC function. Preferably, the enhancer is an enhancer of intracellularly signalling within the APC.

5 The terms "APC function" and "intracellular signalling within the APC" are as defined above.

For the avoidance of doubt, cytokines and molecules containing a CPG motif are not intracellular inducers or enhancers of APC function since they act extracellularly.

10 A further aspect of the invention provides a method of stimulating antigen presentation or of stimulating an immune response in a mammal by administering a pharmaceutically-effective amount of an inducer of NF- $\kappa$ B. Preferably the method is used to treat (including prophylactically) infectious 15 diseases or cancers by stimulating the immune system of the mammal. Infectious diseases include prion-related diseases, including spongiform encephalopathies. The method may be used to treat (including prophylactically) diseases or conditions characterised by aberrant types and/or aberrantly high levels of (harmful) molecules, for example 20 polypeptides, in the body, for example levels of inflammatory mediators (for example cytokine) associated with chronic inflammation; breakdown products of cells or connective tissue matrix, for example fibronectin fragments;  $\beta$ -amyloid polypeptide (associated with Alzheimer's disease). Stimulating an immune response against such molecules may aid removal 25 of the molecules from the body, thereby helping in resolution or prevention of the condition.

It is preferred if the cancer antigen is, or has at least one epitope present in, any of the following:

5 i) normal cellular proteins that are expressed at abnormally high levels in tumours; eg cyclin D1 in a variety of tumours; cyclin E in breast cancer; mdm 2 in a variety of tumours; EGF-R, erb-B2, erb-B3, FGF-R, insulin-like growth factor receptor, Met, myc, p53 and BCL-2 are all expressed in various tumours.

10 ii) normal cellular proteins that are mutated in tumours; eg Ras mutations in a variety of tumours; p53 mutations in a variety of tumours; BCR/ABL translocation in CML and ALL; CSF-1 receptor mutations in AML and MDS; APC mutations in colon cancer; RET mutations in MEN2A, 2B and FMTC; EGFR mutations in gliomas; PML/RARA translocation in PML; E2A-PBX1 translocation in pre B leukaemias and in childhood acute leukaemias.

15 iii) virally encoded proteins in tumours associated with viral infection; eg human papilloma virus proteins in cervical cancer; Epstein-Barr virus proteins in B cell lymphomas and Hodgkin's lymphoma; HTLV-1 proteins in adult T cell leukaemia; hepatitis B and C virus proteins in hepatocellular carcinoma; herpes-like virus proteins in Kaposi's sarcoma.

20 iv) HIV encoded proteins in HIV infected patients.

Thus, the above cancer-associated antigens can be divided into three main categories: (i) normal self antigens expressed at high levels in tumour cells; (ii) mutated self antigens expressed in tumour cells; (iii) viral antigens expressed in tumours associated with viral infection. Category (i) is preferred.

Three subtypes are included in category (i):

- a) normal cellular proteins that are overexpressed;
- b) proteins that are expressed in a tissue-specific fashion in normal cells but also in tumours; and
- c) proteins that are embryonic antigens, silent in most adult tissues but aberrantly expressed in tumours.

5 Examples of b) and c) are:

- 10 b) tissue-specific differentiation antigens as targets for tumour-reactive CTL such as GATA-1, IKAROS, SCL (expressed in the haematopoietic lineage and in leukaemias); and immunoglobulin constant regions (for treatment of multiple myeloma); and
- 15 c) Wilms-tumour antigen 1 (WT1) for treatment of leukaemias and Wilms tumour and carcinoembryonic antigens (CEA a foetal protein) for liver and intestinal tumours.

20 In one embodiment, the cancer - associated antigen may be provided by a crude extract of a tumour sample.

25 Overexpression of oncogene-encoded proteins in human tumours and mutated oncogenes expressed in human tumours are described in Stauss & Dahl (1995) *Tumour Immunology*, Dalgleish/Browning, Chapter 7, incorporated herein by reference.

Thus, it is preferred if the patient to be treated has cancer; more preferably any one of breast cancer; bladder cancer; lung cancer; prostate cancer; thyroid cancer; leukaemias and lymphomas such as CML, ALL, AML,

PML; colon cancer; glioma; seminoma; liver cancer; pancreatic cancer; bladder cancer; renal cancer; cervical cancer; testicular cancer; head and neck cancer; ovarian cancer; neuroblastoma and melanoma.

5 CML is chronic myelocytic leukaemia; ALL is acute lymphoblastic leukaemia; AML is acute myelocytic leukaemia; and PML is pro-myelocytic leukaemia.

Alternatively, the patient have have or be at risk of any disease caused by a  
10 pathogen, particularly a bacterium, yeast, virus, trypanosome and the like. It is preferred if the disease is caused by a chronic infection with a pathogen. It is also preferred if the pathogen is one which is not readily cleared by the host immune system.

15 It is preferred if the disease is a viral infection; more preferably a disease caused by any one of HIV, papilloma virus, Epstein-Barr virus, HTLV-1, hepatitis B virus, hepatitis C virus, herpes virus or any virus that causes chronic infection. It is particularly preferred if the virus is HIV.

20 Abnormally elevated amounts of a hormone produced by cells occur in some diseases such as certain types of thyroid disease. Thus, the method of the invention may be used to promote ablation of cells producing the elevated amounts of the hormone. The antigen may be the hormone the biosynthetic enzymes involved in synthesis of the hormone, which may be 25 overproduced by the cell.

Patients with a bacterial infection, particularly an infection that causes chronic infection may also be usefully treated. The bacterial infection may

be an intracellular infection. Thus, the method may be useful in treating tuberculosis.

5 The inventors have realised that the pivotal role of NF- $\kappa$ B allows it to be stimulated to produce an increase in the immune response within the mammal, for example human.

10 A further aspect of the invention provides an NF- $\kappa$ B inducer for use as a medicament, in particular as an immune response stimulant. The NF- $\kappa$ B inducer may be used as an anti-infectious disease agent or as an anti-cancer agent or in treating diseases or conditions characterised by aberrant types and/or aberrantly high levels of (harmful) molecules as discussed above.

15 Increasing the immune response in patients having an infectious disease or cancer or condition characterised by aberrant types and/or aberrantly high levels of molecules in the body will help to treat the patient by increasing the body's own immune response against the infectious disease or cancer or condition.

20 20 A further aspect of the invention provides an NF- $\kappa$ B inducer for use in the manufacture of a medicament to stimulate an immune response. Preferably the inducer is used to treat an infectious disease or a cancer or a condition as defined above.

25 Preferred NF- $\kappa$ B inducers include MEKK1, NIK, IKK1, IKK2, TRAF2, TRAF5, TRAF6, TAK, TPL-2 or Rel B or other NF- $\kappa$ B subunits e.g. p65 or cRel. Fragments and muteins of such inducers capable of inducing an NF- $\kappa$ B may also be used. The inducers may be encoded by suitable vectors, as

described above for NF- $\kappa$ B inhibitors, and introduced into the cells of a patient to be treated.

A preferred NF- $\kappa$ B inducer may be a dominant negative mutant of MyD88 (ie capable of inhibiting signalling by wild-type MyD88 molecules, for example in a cell in which wild-type and inhibitory MyD88 molecules are present). The inhibition may arise from blocking interaction of endogenous wild-type MyD88 with a binding partner of the endogenous MyD88, for example a Toll-Like Receptor (TLR). The dominant negative mutant may 5 be MyD88lpr (Burns *et al* (1998) *J Biol Chem* 273(20), 12203-12209) or a fragment of MyD88 lacking a death domain (see Burns *et al* (1998) and references reviewed therein). The MyD88 (myeloid differentiation protein) is considered to have a modular organisation consisting of an N-terminal 10 death domain (DD) separated by a short linker from a C-terminal Toll domain (reviewed in Burns *et al* (1998)). The N-terminal DD is related to a motif of approximately 90 amino acids that is considered to mediate protein-protein interactions with other DD sequences forming either homo- 15 or heterodimers (Boldin *et al* (1995) *J Biol Chem* 270, 387-391).

20 The inhibitory MyD88 molecule may be a MyD88 molecule that is less able than MyD88, preferably substantially unable, to bind to a DD, for example the DD of MyD88 or of IRAK. For example, the inhibitory MyD88 may be less able than MyD88, preferably substantially unable, to dimerise *via* the 25 DD. The inhibitory MyD88 molecule may be a truncated version of MyD88, for example a MyD88 molecule in which all or part of the domain termed the Death Domain is deleted. It may be a mutated MyD88 molecule, for example a MyD88 molecule that is mutated in the DD, for example with a non-conservative mutation. For example, it may be mutated at the position equivalent to Phe56 of full length mouse MyD88, for example to

Asn. It may be the mutated MyD88 molecule termed MyD88lpr, as noted above in which the N terminal 53 amino acids of My D88 are also absent Burns *et al* (1998) *J. Biol. Chem.* 273, 12203-12209. MyD88lpr has a point mutation (F56N; mouse sequence numbering) when compared with wild-type MyD88, for example mouse wild-type MyD88. This point mutation is in the DD and prevents dimerisation of the DD (Burns *et al* (1998)). The mutation corresponds to the lpr<sup>cp</sup> mutation known to abolish cytotoxic signalling of Fas, probably by disrupting the conformation of the DD domain (Nagata (1994) *Semin Immunol* 6, 3-8; Huang *et al* (1996) *Nature* 384, 638-641).

The constructs for the wild-type MyD88 and dominant negative MyD88 (MyD88-1pr) has been published (Burns K. *et al* *J. Biol Chem* 1998) but MyD88-1pr is wrongly described as a single amino acid mutation in its death domain, where Phe<sup>56</sup> is mutated to Asn. This mutation corresponds to the 1pr<sup>cp</sup> mutation present in the death domain of Fas ligand which abolishes its downstream signalling by disrupting the conformation of the death domain. Actually, in addition to the point mutation there is a deletion in its N-terminal domain of 53 amino acids (1-159 base pairs of the genebank sequence are missing). This deletion results in part of the death domain missing.

It is preferred that the inhibitory MyD88 comprises a functional Toll domain, ie a Toll domain that is capable of interacting with a Toll domain, for example the Toll domain of a wild-type MyD88, for example wild-type human or mouse MyD88 or a TLR. It is preferred that the inhibitory MyD88 comprises the full-length MyD88 Toll domain. A full-length Toll domain may be necessary for Toll-Toll domain interaction.

Methods of measuring protein-protein interactions (and their enhancement or disruption) will be well known to those skilled in the art. Suitable methods of measuring DD and Toll-Toll interactions are also described in Burns *et al* (1998). Suitable methods may include, for example, yeast two-hybrid interactions, co-purification, ELISA, co-immunoprecipitation, fluorescence resonance energy transfer (FRET) techniques and surface plasmon resonance methods. Thus, a MyD88 molecule may be considered capable of binding to or interacting with a DD or Toll domain if an interaction may be detected between the said MyD88 polypeptide and a polypeptide comprising a DD or Toll domain by ELISA, co-immunoprecipitation or surface plasmon resonance methods or by a yeast two-hybrid interaction or copurification method. The preferred method is surface plasmon resonance.

Preliminary work indicates that MEKK1 can induce NF- $\kappa$ B and enhance APC such as DC function. It is preferred that the inducer is capable of inducing NF- $\kappa$ B in DC or precursors thereof. Thus, inducers or enhancers of APC function may be useful in vaccine production. Similarly, inhibitors of APC function may be useful in preventing cells recognising a particular antigen and inducing an anergic state.

Thus, the invention provides a molecule comprising (1) a portion (modulating portion) comprising or encoding an intracellular modulator, for example an intracellular inhibitor or an intracellular enhancer of antigen-presenting cell (APC), such as DC, function and (2) a portion comprising or encoding an antigenic molecule (antigenic portion). In particular, the invention provides a polynucleotide encoding an antigen and a modulator, for example an inhibitor or an enhancer of DC function. Preferably, the molecule is or comprises a DNA vaccine encoding an antigen and an

enhancer of APC, such as DC, function. The modulator, for example enhancer of APC, such as DC, function may be an intracellular signalling molecule or derivative thereof which retains or has enhanced intracellular signalling activity. It is preferred if the derivative is one which retains or 5 enhances DC function. It is preferably an activator/inducer of NF- $\kappa$ B. It may be NF- $\kappa$ B or a component thereof. The DNA vaccine may comprise a recombinant polynucleotide comprising a portion encoding the enhancer of APC, such as DC function and a portion encoding an antigenic molecule. Alternatively, the antigenic molecule may be encoded on a separate 10 polynucleotide molecule; this is less preferred.

It will be appreciated that preferred inhibitors as described may be used.

Preferred enhancers are MEKK and a dominant negative mutant of My 15 D88, for example My D881pr.

It will be appreciated that the preferred enhancers/inducers as described above may be used in the vaccines of the invention.

20 The antigenic molecule may comprise more than one copy of one or more epitopes. For example, it may comprise a single copy of a single epitope-forming amino acid sequence, for example a sequence of between about 8 and 30 amino acids, preferably about 10 to 18 amino acids, still more preferably about 15 amino acids in length. It may comprise multiple copies 25 of such an epitope-forming sequence, or single or multiple copies of at least two different epitope-forming sequences. The antigenic sequences may be concatenated to form a domain-like structure, or may be disposed at different points in a carrier polypeptide. The polynucleotide may encode

one or several different antigenic molecules, each of which may have one or more antigenic portions or epitopes.

The invention also includes DNA vaccines encoding an inducer of NF- $\kappa$ B for use in the invention. Such vaccines could include DNA sequences incorporating an antigen of interest derived from a pathogen, e.g. hepatitis A, B, C, etc, HIV, HTLV, influenza, tuberculoses, malaria or alternatively a cancer specific antigen or aberrant molecules such as  $\beta$ -amyloid, as discussed above, or a prion. In addition, such vaccines would also include an activator of NF $\kappa$ B, possibly two or more activators of NF $\kappa$ B for maximum effect. Both antigen and activator would be under the control of suitable promoter sequences to regulate expression of antigen and activators. An alternative method of stimulating an immune response may be to provide a vector comprising a nucleic acid sequence encoding an NF- $\kappa$ B inducer operatively linked to regulatory elements necessary for expressing said sequence. The vector may comprise an inducible promoter to enable an increased immune response to be produced by the increased activation of NF- $\kappa$ B.

The use of recombinant polyepitope vaccines for the delivery of multiple CD8 CTL epitopes is described in Thomson *et al* (1996) *J. Immunol.* **157**, 822-826 and WO 96/03144, both of which are incorporated herein by reference. In relation to the present invention, it may be desirable to include in a single vaccine, a peptide (or a nucleic acid encoding a peptide) wherein the peptide includes, in any order, one or more antigenic amino acid sequences (for example each of between about 8 and 18 amino acids in length), for example derived from a tumour-associated antigen, and a CD4 T cell-stimulating epitope (such as from tetanus toxoid). Such "bead-on-a-string" vaccines are typically DNA vaccines.

The antigenic molecule may comprise an epitope present on transformed or cancerous cells (ie a tumour-associated antigen or epitope, for example the MAGE-1 antigen produced by a high proportion of human melanoma

5       tumours (van der Bruggen *et al* (1991) *Science* **254**, 1643)). Alternatively, it may comprise an epitope present on a pathogenic organism, for example a virus, or on a cell (preferably a human cell) infected by a pathogenic organism, for example a virally-infected cell, as noted above.

10      The epitope may be a T-cell epitope ie an epitope that is capable of inducing a T-cell response (TH-1 response), preferably a CD8+ cytotoxic T-cell response, but alternatively a CD4+ helper T-cell response (TH-2 response) as well known to those skilled in the art. A cytotoxic T-cell response may be undesirable in certain cases, for example when the antigen is a

15      mycobacterial antigen (for example *Mycobacterium tuberculosis* or *M. leprae* antigen).

The inhibitor or inducer or antigen may be a peptidomimetic compound, for example a peptidomimetic compound corresponding to a polypeptide

20      inhibitor or inducer discussed above.

The term “peptidomimetic” refers to a compound that mimics the conformation and desirable features of a particular peptide as a therapeutic agent, but that avoids potentially undesirable features. For example,

25      morphine is a compound which can be orally administered, and which is a peptidomimetic of the peptide endorphin.

Therapeutic applications involving peptides may be limited, due to lack of oral bioavailability and to proteolytic degradation. Typically, for example,

peptides are rapidly degraded *in vivo* by exo- and endopeptidases, resulting in generally very short biological half-lives. Another deficiency of peptides as potential therapeutic agents is their lack of bioavailability via oral administration. Degradation of the peptides by proteolytic enzymes in the 5 gastrointestinal tract is likely to be an important contributing factor. The problem is, however, more complicated because it has been recognised that even small, cyclic peptides which are not subject to rapid metabolite inactivation nevertheless exhibit poor oral bioavailability. This is likely to be due to poor transport across the intestinal membrane and rapid clearance 10 from the blood by hepatic extraction and subsequent excretion into the intestine. These observations suggest that multiple amide bonds may interfere with oral bioavailability. It is thought that the peptide bonds linking the amino acid residues in the peptide chain may break apart when the peptide drug is orally administered.

15 There are a number of different approaches to the design and synthesis of peptidomimetics. In one approach, such as disclosed by Sherman and Spatola, *J. Am. Chem. Soc.*, 112: 433 (1990), one or more amide bonds have been replaced in an essentially isoteric manner by a variety of chemical 20 functional groups. This stepwise approach has met with some success in that active analogues have been obtained. In some instances, these analogues have been shown to possess longer biological half-lives than their naturally-occurring counterparts. Nevertheless, this approach has limitations. Successful replacement of more than one amide bond has been 25 rare. Consequently, the resulting analogues have remained susceptible to enzymatic inactivation elsewhere in the molecule. When replacing the peptide bond it is preferred that the new linker moiety has substantially the same charge distribution and substantially the same planarity as a peptide bond.

Retro-inverso peptidomimetics, in which the peptide bonds are reversed, can be synthesised by methods known in the art, for example such as those described in Mézière *et al* (1997) *J. Immunol.* **159** 3230-3237. This 5 approach involves making pseudopeptides containing changes involving the backbone, and not the orientation of side chains. Retro-inverse peptides, which contain NH-CO bonds instead of CO-NH peptide bonds, are much more resistant to proteolysis.

10 In another approach, a variety of uncoded or modified amino acids such as D-amino acids and N-methyl amino acids have been used to modify mammalian peptides. Alternatively, a presumed bioactive conformation has been stabilised by a covalent modification, such as cyclisation or by incorporation of  $\gamma$ -lactam or other types of bridges. See, eg. Veber *et al*, 15 *Proc. Natl. Acad. Sci. USA*, 75:2636 (1978) and Thurnsell *et al*, *Biochem. Biophys. Res. Comm.*, 111:166 (1983).

A common theme among many of the synthetic strategies has been the introduction of some cyclic moiety into a peptide-based framework. The 20 cyclic moiety restricts the conformational space of the peptide structure and this frequently results in an increased affinity of the peptide for a particular biological receptor. An added advantage of this strategy is that the introduction of a cyclic moiety into a peptide may also result in the peptide having a diminished sensitivity to cellular peptidases.

25

One approach to the synthesis of cyclic stabilised peptidomimetics is ring closing metathesis (RCM). This method involves steps of synthesising a peptide precursor and contacting it with a RCM catalyst to yield a conformationally restricted peptide. Suitable peptide precursors may contain

two or more unsaturated C-C bonds. The method may be carried out using solid-phase-peptide-synthesis techniques. In this embodiment, the precursor, which is anchored to a solid support, is contacted with a RCM catalyst and the product is then cleaved from the solid support to yield a 5 conformationally restricted peptide.

Polypeptides in which one or more of the amino acid residues are chemically modified, before or after the polypeptide is synthesised, may be used as antigen providing that the function of the polypeptide, namely the production 10 of a specific immune response *in vivo*, remains substantially unchanged. Such modifications include forming salts with acids or bases, especially physiologically acceptable organic or inorganic acids and bases, forming an ester or amide of a terminal carboxyl group, and attaching amino acid protecting groups such as N-t-butoxycarbonyl. Such modifications may 15 protect the polypeptide from *in vivo* metabolism.

A further aspect of the invention provides a kit of parts or composition of chimaeric molecule, comprising (1) an intracellular modulator, for example intracellular inhibitor or intracellular enhancer, of APC, such as DC, 20 function and (2) and antigenic portion comprising or encoding an antigenic molecule.

A further aspect of the invention comprises a kit of parts, composition or a chimaeric molecule, for example chimaeric polypeptide, comprising a NF- $\kappa$ B inhibiting or activating/inducing portion and an antigenic portion, as 25 defined above.

Either or both portions in these aspects of the invention may further comprise a translocating portion and/or a cell binding portion. The cell

binding portion is preferably capable of binding to a dendritic cell or precursor thereof. The translocating portion may aid in internalisation of the molecule or at least the antigenic portion and preferably the signalling inhibiting or enhancing portion. Thus, exogenously applied peptides may be linked to a HIV tat peptide. This may direct them into the MHC Class I pathway for presentation by CTL (see, for example, Kim *et al* (1997) *J. Immunol.* **159**, 1666-1668. Chimaeric molecules which may be adapted in accordance with the present invention are described in WO95/31483.

10 Dendritic cells may be characterised by expression of the CD80, CD86, CD40, CD1a, HLA-DR and/or CD83 cell surface molecules. Immature dendritic cells may be CD34<sup>+</sup> or CD14<sup>+</sup>. Thus, the cell binding portion may be capable of binding to one or more of these cell surface molecules (for example, an antibody capable of binding to such a molecule).

15 Immature DCs show increased antigen capture and processing. They show high intracellular MHC Class I and II; increased endocytosis and phagocytosis; high CCR1, CCR5 and CCR6; low CCR7; high CD68; low CD40, CD54, CD80, CD83, and CD86; and no DC-LAMP.

20 Mature DCs show increased antigen processing. They show high surface MHC Class I and II; low endocytosis and phagocytosis; low CCR1, CCR5 and CCR6; high CCR7; low CD68; high CD40, CD54, CD58, CD80, CD83 and CD86; high DC-LAMP; and high p55 fascin.

25 Such a cell binding portion may be useful in directing any inhibitor or activator as herein described, for example nucleic acid, DNA vaccine or antibody, to an APC such as a DC or immature DC.

Preferably, the polynucleotide or DNA vaccine is capable of expressing the encoded antisense molecule or polypeptide(s) in the patient, still more preferably in an APC such as a DC or immature DC of the patient. The antisense molecule or polypeptide(s), for example NF- $\kappa$ B inhibitor or 5 inducer/activator, or antigen, as appropriate, may be expressed from any suitable polynucleotide (genetic construct) as is described herein and delivered to the patient. Typically, the genetic construct which expresses the antisense molecule or polypeptide comprises the said polypeptide coding sequence operatively linked to a promoter which can express the 10 transcribed polynucleotide (eg mRNA) molecule in a cell of the patient, which may be translated to synthesise the said polypeptide. Suitable promoters will be known to those skilled in the art, and may include promoters for ubiquitously expressed, for example housekeeping genes or for tissue-specific genes, depending upon where it is desired to express the 15 said polypeptide (for example, in dendritic cells or precursors thereof). Preferably, a dendritic cell or dendritic precursor cell-selective promoter is used, but this is not essential, particularly if delivery or uptake of the polynucleotide is targeted to the selected cells ie dendritic cells or precursors.

20

Promoters that may be selective for dendritic cells may be promoters from the CD36 or CD83 genes.

Targeting the vaccine to specific cell populations, for example antigen 25 presenting cells, may be achieved, for example, either by the site of injection, use of targeting vectors and delivery systems, or selective purification of such a cell population from the patient and *ex vivo* administration of the peptide or nucleic acid (for example dendritic cells may be sorted as described in Zhou *et al* (1995) *Blood* 86, 3295-3301; Roth

*et al* (1996) *Scand. J. Immunology* **43**, 646-651). In addition, targeting vectors may comprise a tissue- or tumour-specific promoter which directs expression of the antigen at a suitable place.

5 As noted above, it may be desirable to use an inducible promoter. It will be appreciated that it may be desirable to be able to regulate temporally expression of the polypeptide(s) (for example NF- $\kappa$ B inhibitor or activator/inducer) in the cell. Thus, it may be desirable that expression of the polypeptide(s) is directly or indirectly (see below) under the control of a

10 promoter that may be regulated, for example by the concentration of a small molecule that may be administered to the patient when it is desired to activate or repress (depending upon whether the small molecule effects activation or repression of the said promoter) expression of the polypeptide. It will be appreciated that this may be of particular benefit if the expression

15 construct is stable ie capable of expressing the polypeptide (in the presence of any necessary regulatory molecules) in the said cell for a period of at least one week, one, two, three, four, five, six, eight months or more. A preferred construct of the invention may comprise a regulatable promoter. Examples of regulatable promoters include those referred to in the

20 following papers: Rivera *et al* (1999) *Proc Natl Acad Sci USA* **96**(15), 8657-62 (control by rapamycin, an orally bioavailable drug, using two separate adenovirus or adeno-associated virus (AAV) vectors, one encoding an inducible human growth hormone (hGH) target gene, and the other a bipartite rapamycin-regulated transcription factor); Magari *et al* (1997) *J*

25 *Clin Invest* **100**(11), 2865-72 (control by rapamycin); Bueler (1999) *Biol Chem* **380**(6), 613-22 (review of adeno-associated viral vectors); Bohl *et al* (1998) *Blood* **92**(5), 1512-7 (control by doxycycline in adeno-associated vector); Abruzzese *et al* (1996) *J Mol Med* **74**(7), 379-92 (reviews induction factors e.g., hormones, growth factors, cytokines, cytostatics, irradiation,

heat shock and associated responsive elements). Tetracycline – inducible vectors may also be used. These are activated by a relatively –non toxic antibiotic that has been shown to be useful for regulating expression in mammalian cell cultures. Also, steroid-based inducers may be useful especially since the steroid receptor complex enters the nucleus where the DNA vector must be segregated prior to transcription.

This system may be further improved by regulating the expression at two levels, for example by using a tissue-specific promoter and a promoter controlled by an exogenous inducer/repressor, for example a small molecule inducer, as discussed above and known to those skilled in the art. Thus, one level of regulation may involve linking the appropriate polypeptide-encoding gene to an inducible promoter whilst a further level of regulation entails using a tissue-specific promoter to drive the gene encoding the requisite inducible transcription factor (which controls expression of the polypeptide (for example NF- $\kappa$ B inhibitor or inducer/activator-encoding gene) from the inducible promoter. Control may further be improved by cell-type-specific targeting of the genetic construct.

- 20 The methods or constructs of the invention may be evaluated in, for example, APCs such as dendritic cells generated *in vitro*, as known to those skilled in the art, before evaluation in whole animals. Suitable methods are described in Example 1.
- 25 The genetic constructs of the invention can be prepared using methods well known in the art.

A further aspect of the invention provides vectors, vaccines and antibodies for use in the invention.

The vaccines and vectors of the invention (therapeutic molecules of the invention) may be formulated with suitable pharmaceutically-acceptable carriers, fillers or other additives. They may be administered by any suitable means such as intra-muscularly, intra-veinally, orally, anally, intra-nasally, etc. Subcutaneous or intramuscular administration may be preferred. It will be appreciated that an inducer, for example small molecule inducer as discussed above may preferably be administered orally.

- 5 10 It may be desirable to locally perfuse an area comprising target cells with the suitable delivery vehicle comprising the therapeutic molecule, for example genetic construct, for a period of time; additionally or alternatively the delivery vehicle or therapeutic molecule can be injected directly into accessible areas comprising target cells, for example subcutaneously.
- 15 Methods of delivering genetic constructs, for example adenoviral vector constructs to cells of a patient will be well known to those skilled in the art.

In particular, an adoptive therapy protocol may be used or a gene gun may be used to deliver the construct to dendritic cells, for example in the skin.

- 20 25 An adoptive therapy approach may include the steps of (1) obtaining antigen presenting cells or precursors thereof, preferably dendritic cells or precursors thereof, from the patient; (2) contacting said antigen presenting cells with a NF- $\kappa$ B inhibitor or inducer/activator as described herein, and optionally antigen to which an immune response is required, or chimaeric molecule or polynucleotide as discussed above, *ex vivo*; and (3) reintroducing the so treated antigen presenting cells into the patient.

Suitably, the dendritic cells are autologous dendritic cells which are pulsed with polypeptide(s), for example a NF- $\kappa$ B activator and an antigen. T-cell therapy using autologous dendritic cells pulsed with peptides from a tumour associated antigen is disclosed in Murphy *et al* (1996) *The Prostate* **29**, 371-380 and Tjua *et al* (1997) *The Prostate* **32**, 272-278.

In a further embodiment the antigen presenting cells, such as dendritic cells, are contacted with a polynucleotide which encodes the NF- $\kappa$ B inhibitor or activator/inducer. The polynucleotide may be any suitable polynucleotide and it is preferred that it is capable of transducing the dendritic cell thus resulting in respectively activation or inhibition of antigen presentation by the antigen presenting cell.

Conveniently, the polynucleotide may be comprised in a viral polynucleotide or virus, as noted above. For example, adenovirus-transduced dendritic cells have been shown to induce antigen-specific antitumour immunity in relation to MUC1 (see Gong *et al* (1997) *Gene Ther.* **4**, 1023-1028). Similarly, adenovirus-based systems may be used (see, for example, Wan *et al* (1997) *Hum. Gene Ther.* **8**, 1355-1363); retroviral systems may be used (Specht *et al* (1997) *J. Exp. Med.* **186**, 1213-1221 and Szabolcs *et al* (1997) *Blood* **90**, 2160-2167); particle-mediated transfer to dendritic cells may also be used (Tuting *et al* (1997) *Eur. J. Immunol.* **27**, 2702-2707); and RNA may also be used (Ashley *et al* (1997) *J. Exp. Med.* **186**, 1177-1182).

25

The APCs, such as dendritic cells, may be derived from the patient (ie autologous dendritic cells) or from a healthy individual or individuals (MHC matched or mismatched), treated *in vitro* as indicated above, followed by adoptive therapy, ie introduction of the so-manipulated

dendritic cells *in vivo*, which may then activate CTL responses. By "healthy individual" we mean that the individual is generally in good health, preferably has a competent immune system and, more preferably, is not suffering from any disease which can be readily tested for, and detected.

5

Thus, the methods of the invention include methods of adoptive immunotherapy.

10 It is preferred if between about  $10^3$  and  $10^{11}$  DCs are administered to the patient; more preferably between  $10^6$  and  $10^7$  DCs.

15 The APCs such as DCs may be administered by any convenient route. It is preferred if the DCs are administered intravenously. It is also preferred if the DCs are administered locally to the site of the disease (such as a tumour or local viral or bacterial infection). Local administration is particularly preferred for cancer. Conveniently, the DCs are administered into an artery that supplies the site of the disease or the tissue where the disease is located.

20 The cells (or vaccine) may be given to a patient who is being treated for the disease by some other method. Thus, although the method of treatment may be used alone it is desirable to use it as an adjuvant therapy.

The APCs, such as DCs, or vaccine may be administered before, during or after the other therapy.

25

When the disease to be treated is a cancer it is preferable if the cancer has been, is being or will be treated with a conventional therapy or surgery as well as with the method of the invention. Conveniently, depending on the therapy, the cancer is treated by radiotherapy or by chemotherapy.

When the disease to be treated is an infection by a pathogen it is preferable if the infection has been, is being or will be treated with a conventional therapy or surgery.

5

If the patient to be treated has HIV infection it is preferable if the method of the invention is used as an adjuvant to other treatment, for example treatment with a reverse transcriptase inhibitor such as AZT or 3TC or combination therapy for example HART (highly active retroviral therapy).

10

When the method of the invention is used to treat a solid tumour it is preferred if the APCs such as DCs or vaccine are administered as the first post-surgery treatment.

15

When the method of the invention is used to treat leukaemia it is preferred if the APCs such as DCs or vaccine are administered after radiotherapy or chemotherapy. It is also preferred if leukaemia patients are also treated with the DCs in combination with bone marrow transplantation.

20

Cancer therapy, for example adoptive immunotherapy may be most effective in the control or elimination of minimal residual disease rather than in the reduction of bulk disease. It is conceivable that immunotherapy may temporarily increase the dimensions of bulk disease due to influx of cytotoxic T lymphocytes. Extent and bulk of disease may be monitored following therapy but not used as a formal endpoint. Patients are followed up in the routine manner in the long term to ensure that no long term adverse events are manifest.

25

Further delivery or targeting strategies may include the following. Ballistic compressed air driven DNA/protein coated nanoparticle penetration (for example using a BioRad device) of cells in culture or *in vivo* may be used. Constructs for delivery should preferably have cell-type specific promoters.

5

Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.

10 The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.

15 Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind well known to those skilled in the art. Nasal sprays may be a useful format.

20 The dose of the construct, for example, is dependent on the size of the construct and the purpose for which it is administered. In general, the range is calculated based on the surface area of tissue to be treated. The effective dose of construct may be dependent on the size of the construct and the delivery vehicle/targeting method used and chemical composition of the oligonucleotide but a suitable dose may be determined by the skilled person, 25 for example making use of data from the animal and *in vitro* test systems indicated above.

The construct, for example, may be administered to the patient systemically for both therapeutic and prophylactic purposes. The construct, for example

may be administered by any effective method, as described above, for example, parenterally (eg intravenously, subcutaneously, intramuscularly) or by oral, nasal or other means which permit the construct, for example, to access and circulate in the patient's bloodstream. Construct administered 5 systemically preferably are given in addition to locally administered construct, but also have utility in the absence of local administration.

It is believed that uptake of the nucleic acid and expression of the encoded 10 polypeptide by dendritic cells may be the mechanism of priming of the immune response; however, dendritic cells may not be transfected but are still important since they may pick up expressed peptide from transfected 15 cells in the tissue.

It is preferred if the vaccine, such as DNA vaccine, is administered into the 15 muscle. It is also preferred if the vaccine is administered onto or into the skin.

As noted above, the invention provides a kit of parts or composition or a 20 chimaeric molecule, comprising (1) a modulating portion comprising or encoding a NF- $\kappa$ B inhibitor or inducer and (2) an antigenic portion comprising or encoding an antigenic molecule.

In relation to any previous aspect of the invention, particularly a vaccine as 25 previously described, or such a kit, chimaeric molecule or composition, the antigenic molecule preferably comprises an epitope present on transformed or cancerous cells or on a pathogenic organism, or on a cell infected by a pathogenic organism.

Thus, the invention provides a vaccine effective against cancer, or cancer or tumour cells, or against a pathogenic organism or cell infected with a pathogenic organism, comprising an effective amount of an NF- $\kappa$ B inducer or other inducer of APC function as described above or polynucleotide 5 encoding an NF- $\kappa$ B inducer or other inducer of APC function. The vaccine preferably further comprising an antigen or polynucleotide encoding an antigen, having an epitope present on the cancer or tumour cells, or the pathogenic organism or cell infected with a pathogenic organism. The vaccine is preferably a nucleic acid vaccine.

10

A further aspect of the invention provides a pharmaceutical composition comprising a NF- $\kappa$ B inducer, NF- $\kappa$ B inhibitor, vaccine, molecule, polynucleotide, kit of parts, composition or chimaeric molecule of any of the preceding aspects of the invention and a pharmaceutically acceptable 15 carrier.

The invention further provides a vaccine, molecule, polynucleotide, kit of parts, composition or chimaeric molecule of any preceding aspect of the invention for use in medicine. The invention still further provides the use of 20 a vaccine, molecule, polynucleotide, kit of parts, composition or chimaeric molecule of any of the preceding aspects of the invention in the manufacture of a medicament for the treatment of a patient in need of modulation of antigen presentation.

25 It will be clear that the invention provides a method of killing target cells in a patient which target cells aberrantly express a first epitope, the method comprising the steps of (1) obtaining APCs, such as dendritic cells, from said patient; (2) contacting said APCs, such as dendritic cells, with an enhancer of APC, such as DC, function *ex vivo*; (3) optionally contacting

said cells with the said epitope or with a polynucleotide or expression vector encoding the said epitope and (4) reintroducing the so treated APCs such as dendritic cells, into the patient.

5 It will also be clear that the invention provides a method of killing target cells in a patient which target cells aberrantly express a first epitope, the method comprising the steps of (1) obtaining dendritic cells from said patient; (2) contacting said dendritic cells with a NF- $\kappa$ B inducer *ex vivo*; (3) optionally contacting said cells with the said epitope or with a polynucleotide or expression vector encoding the said epitope and (4) reintroducing the so treated dendritic cells into the patient.

10

The target cells may be cancer cells.

15 The invention also provides methods of inhibiting or stimulating the maturation and activation of dendritic cells *in vivo* or *in vitro* comprising administering an effective amount of an inhibitor or inducer of NF- $\kappa$ B.

The inhibitors or inducers may be as defined above.

20

For the avoidance of doubt, wherever the term "dendritic cell" or "dendritic cells" are used the term includes any suitable antigen presenting cell unless the context suggests otherwise. It is preferred that the antigen presenting cell is a dendritic cell.

25

Preferred embodiments of the invention will now be described.

## FIGURES LEGENDS

5 **Figure 1.** Cell viability of DC treated with PSI. Mature DC was either left untreated, or treated with various doses of PSI for 4h. After wash, cells were cultured in RPMI 1640 supplemented as described without monocyte condition medium. 6 days after treatment, cells were resuspended in PBS containing 10 µg/ml. Of propidium iodide PI and analysed on FACS scan.

10 **Figure 2.** Immunostimulatory capacity of DC treated with the proteosome inhibitor Cbz-Ile-Glu(O-tert-butyl)-Ala-leucinal (PSI). Mature DC was treated with PSI (0.1 µM : ▲), (0.5 µM : ■), (1, µM :●) or without PSI (○) for 4h. After wash, different numbers of each category of DC and 10<sup>5</sup> cells of allo-lymphocytes were plated on a 96 well plate. Proliferation was determined at day 6 using <sup>3</sup>H-TdR uptake assay. (Each point represents mean +/- SEM from five separate experiments).

15 **Figure 3.** Effect of PSI on the expression of surface antigens was studied using monoclonal antibodies, HLA-DR, CD86 (PE conjugated); Pharmingen, San Diego, CA). on day 6 after PSI treatment, populations of untreated (green line), PSI (0.1 µM) treated (blue dotted line), PSI (1 µM) treated (red dotted line) were phenotyped with the MoAbs listed above and 20 analysed on FACScan (Becton Dickinson).

25 **Figure 4.** Lack of recovery of proliferation response in allo-MLR. Mature DC was treated with vehicle (A) or PSI (1 µM) (B) for 4h. After wash graded number of each treated DC and 10<sup>5</sup> cells of allo-lymphocytes were plated on a 96 well plate with vehicle (○,●), 2 ng/ml. of IL-2 (□,■) or 10 g/ml. of anti CD28 Ab (Δ,▲). Proliferation was determined at day 6 using <sup>3</sup>H-TdR uptake assay. (Each point represents mean +/- SEM from three separate experiments).

Figure 5. PSI pre-treated DC inhibit the growing ability of lymphocytes in allo-MLR. Mature DC was treated with PSI as described above. After washing, each DC was mixed to make different compositions: vehicle treated DC only (○),  $\frac{1}{4}$  number of PSI treated DC mixed with  $\frac{3}{4}$  vehicle treated DC (●),  $\frac{1}{8}$  number of PSI treated DC mixed with  $\frac{7}{8}$  vehicle treated DC (■), or PSI treated DC only (▲). Graded number of each mixture and  $10^5$  cells of allo-lymphocytes were plated on a 96 well plate. Proliferation was determined at day 6 by  $^3$ H-TdR uptake assay.

Figure 6. Impaired response of allo-lymphocytes pre-cultured with PSI treated or non-treated DC. Lymphocytes were co-cultured with 1/10 number of PSI treated (●,▲) or non-treated DC (○,△). After 2 days, each DC were removed by CD83, CD86 coated plate. Lymphocytes were cultured for another 4 days using vehicle treated DC (○,●), or PSI (1  $\mu$ M) treated DC (△,▲). Proliferation was determined by  $^3$ H-TdR uptake assay. (Each point represents mean +/- SEM from three separate experiments).

Figure 7. Reduced expression of surface antigens on allo-lymphocytes by PSI pre-treated DC. Lymphocytes were cultured for 6 days as the same conditions with allo-MLR experiment using vehicle treated DC (green line), or PSI (1  $\mu$ M) treated DC (red line). Each lymphocytes were phenotyped with MoAbs, CD3, CD25 (PE conjugated; Pharmingen), (CD54) (PE conjugated; Serotec), CD50 (FITC conjugated; Serotec) and analysed by FACScan.

25

Figure 8. Cytokine production of allo-lymphocytes co-cultured with vehicle treated or PSI treated DC. Mature DC was treated with vehicle or PSI (1  $\mu$ M) as described above. Allo-lymphocytes and each DC were plated at  $2 \times 10^5$  cells per well on a 96 well plate and stimulated with PMA (10

nM) or left unstimulated for 49 hr. Supernatants were analysed for IL-2, IL-4, and interferon- $\gamma$  by ELISA.

**Figure 9.** Cytokine productions of DC treated with vehicle or PSI. Mature DC was treated with vehicle or PSI (1 $\mu$ M) as described above. Each DC and allo-lymphocytes were plated at  $2 \times 10^5$  cells per well on a 96 well plate and stimulated with PMA (10 nM) or left unstimulated for 48 hr. Supernatants were analysed for IL-6, IL-8, IL-12 and TNF $\alpha$  by ELISA.

10 **Figure 10.** Expression of MEKK-1 greatly enhances monocyte-derived dendritic cells antigen-presentation in the allogeneic MLR. Briefly, dendritic cells were generated by culturing peripheral blood monocytes with 50 ng/ml. GM-CSF and 10 ng/ml. IL-4. At day 5, they were infected for 2 hours with an adenovirus without insert or encoding MEKK-1 (m.o.i. 15 100:1), or were left uninfected. After 2 days,  $10^4$  dendritic cells were cultured with  $10^5$  purified allogeneic T cells for 5 days in 96-well flat-bottomed plates, plused overnight with 0.5  $\mu$ Ci/well and harvested the following day. Dendritic cells encoding MEKK-1 were 4-fold more powerful in inducing T cell proliferation than uninfected DC, whereas this 20 was not true for dendritic cells infected with an adenovirus without insert.

**Figure 11: Expression of dominant negative inhibitor of MyD88 (MyD88lpr) in dendritic cells induces NF- $\kappa$ B activation**

25 Immature DC were generated from peripheral blood monocytes after 5 days  
of culture with 50 ng/ml GM-CSF and 10 ng/ml IL-4. Then, they were left  
uninfected, or infected in serum-free medium with a control adenovirus  
without insert (Ad0) and an adenovirus encoding dominant-negative  
MyD88 (AdMyD88-lpr). A multiplicity of infection of 100 was used. After  
6h and 24h expression, cells were lysed and their nuclear extracts examined

for NF- $\kappa$ B DNA-binding activity by EMSA. Surprisingly, expression of MyD88lpr could induce on its own NF- $\kappa$ B activation which is totally in contrast with what has been previously found.

5 **Figure 12: Expression of dominant negative (inhibitor) but not wild-type MyD88 induces TNF $\alpha$  production on its own and does not inhibit LPS-induced TNF $\alpha$  production in dendritic cells**

Immature DC were generated from peripheral blood monocytes after 5 days of culture with 50 ng/ml GM-CSF and 10 ng/ml IL-4. Then, they were left 10 uninfected, or infected in serum-free medium with a control adenovirus encoding  $\beta$ -gal (Ad $\beta$ -gal), an adenovirus encoding dominant-negative MyD88 (Adlpr) and an adenovirus encoding wild-type MyD88 (AdMyD88wt). Adtoll has been shown to be non-functional and should be ignored. A multiplicity of infection of 100 was used. After 24 h, cells were 15 stimulated with 100 ng/ml LPS. Surprisingly, expression of dominant negative MyD88 could induce dendritic cell TNF $\alpha$  production on its own, in the absence of additional stimulation. Moreover, it could not inhibit LPS-induced TNF $\alpha$  production, a finding that is in contrast to previous findings.

20 **Figure 13: Expression of wild-type MyD88 abrogates the MyD88-lpr(dominant-negative)-induced TNF $\alpha$  production in dendritic cells**

Immature DC were generated from peripheral blood monocytes after 5 days of culture with 50 ng/ml GM-CSF and 10 ng/ml IL-4. Then, they were left uninfected, or infected in serum-free medium with a control adenovirus 25 encoding  $\beta$ -gal (Ad $\beta$ -gal), an adenovirus encoding wild-type MyD88 (AdMyD88wt) and an adenovirus encoding dominant-negative MyD88 (AdMyD88lpr). In some cases, double infection by Adlpr and Ad $\beta$ -gal or AdMyD88wt at ratios 1:1 and 1:5 was used. A multiplicity of infection of

100 was used for single infections. After 24 h, supernatants were removed and analysed. Surprisingly, expression of dominant negative MyD88 could induce dendritic cell TNF $\alpha$  production on its own, in the absence of additional stimulation. Wild-type Myd88 was able to inhibit TNF 5 production induced by Myd88lpr.

**Figure 14: Expression of dominant-negative MyD88 in dendritic cells enhances antigen-specific T cell proliferation**

Immature DC were generated from peripheral blood monocytes after 5 days 10 of culture with 50 ng/ml GM-CSF and 10 ng/ml IL-4. Then, they were left uninfected, or infected in serum-free medium with a control adenovirus without insert (Ad0), an adenovirus encoding green fluorescent protein as a prototype antigen (AdGFP), and an adenovirus encoding GFP linked together with the dominant negative MyD88 (AdGFP-lpr). After 48 h, 15 graded doses of dendritic cells were cultured with  $2 \times 10^4$  antigen-specific T cells and proliferation was measured at day 3. Delivery of the antigen GFP to dendritic cells induced antigen-specific T cell proliferation that was enhanced by expression of dominant negative MyD88. This is in agreement with our unexpected result that inhibition of MyD88 activity in dendritic 20 cells, induces dendritic cell activation.

**Figure 15: Expression of dominant-negative MyD88 in dendritic cells enhances the allogeneic mixed lymphocyte reaction (MLR)**

Immature DC were generated from peripheral blood monocytes after 5 days 25 of culture with 50 ng/ml GM-CSF and 10 ng/ml IL-4. Then, they were left uninfected, or infected in serum-free medium with a control adenovirus without insert (Ad0), and an adenovirus encoding the dominant negative form of MyD88 (Adlpr). After 48 h, graded doses of dendritic cells were cultured with  $1 \times 10^5$  allogeneic T cells and proliferation was measured at

day 6. expression of dominant negative MyD88 enhances the allogeneic T cell proliferation, a finding that is indicative of increased DC antigen presentation.

5 **Figure 16: Expression of dominant-negative MyD88 in dendritic cells enhances the expression of costimulatory molecules (CD80, CD86)**

Immature DC were generated from peripheral blood monocytes after 5 days of culture with 50 ng/ml GM-CSF and 10 ng/ml IL-4. Then, they were left uninfected, or infected in serum-free medium with a control adenovirus 10 encoding GFP, and with an adenovirus encoding dominant negative MyD88 (Adlpr). After 48 h, dendritic cells were collected and stained for CD80 and CD86, two very important costimulatory molecules required for efficient antigen-presenting function. expression of the dominant negative form of MyD88 enhanced CD80 and CD86 cell surface expression, which is 15 indicative of enhanced dendritic cell antigen-presenting function.

**Figure 17: Expression of dominant-negative MyD88 in macrophages induces p38 MAPK phosphorylation**

Human macrophages were differentiated from peripheral blood monocytes 20 by addition of 100 ng/ml M-CSF for 2-3 days in 5% FCS RPMI. Then, they were left uninfected, infected in serum-free medium with a control adenovirus encoding  $\beta$ -gal, or infected with an adenovirus encoding dominant negative MyD88 (Adlpr). An moi of 100 (or 50 in one case) was used as shown. After 6, 24 and 48h, cells were lysed and extracts assayed 25 for p38 MAPK activity using western blotting and phospho-p38 MAPK-specific antibodies. Unexpectedly, expression of dominant-negative MyD88 induces p38 MAPK activity in human macrophages.

**Figure 18: Expression of dominant-negative MyD88 in macrophages induces IRAK phosphorylation**

Human macrophages were differentiated from peripheral blood monocytes by addition of 100 ng/ml M-CSF for 2-3 days in 5% FCS RPMI. HELA cells cultured in 5% FCS DMEM were also used. Both cell types were left uninfected, infected in serum-free medium with a control adenovirus encoding  $\beta$ -gal, an adenovirus encoding wild-type MyD88 or an adenovirus encoding dominant negative MyD88 (AdMyD88lpr). An moi of 100 was used. After 5 min or 12 h, cells were lysed and extracts assayed for IRAK and phospho-IRAK using western blotting. In HELA cells, expression of dominant negative MyD88 (MyD88-lpr) was found to inhibit IL-1-induced activation of IRAK. Unexpectedly, however, expression of dominant-negative MyD88 induces IRAK activity in human macrophages that is not increased by the addition of LPS. This finding suggests that MyD88 activity is also required for an inhibitory signal in macrophages (but not HELA cells) that inhibits IRAK phosphorylation, and its blockade results in the activation of IRAK.

**Figure 19: Expression of dominant-negative MyD88 in macrophages induces I $\kappa$ B $\alpha$  phosphorylation**

Human macrophages were differentiated from peripheral blood monocytes by addition of 100 ng/ml M-CSF for 2-3 days in 5% FCS RPMI. Cells infected in serum-free medium with a control adenovirus encoding  $\beta$ -gal or an adenovirus encoding dominant negative MyD88 (Adlpr). An moi of 100 was used. After 24h, cells were lysed and extracts assayed for phospho-I $\kappa$ B $\alpha$  using western blotting. Unexpectedly, expression of dominant-negative MyD88 induces I $\kappa$ B $\alpha$  phosphorylation in human macrophages.

**Figure 20: Expression of dominant-negative but not wild-type MyD88 in macrophages induces TNF $\alpha$ , IL-6 and IL-8 production in the absence of any stimulus.**

Human macrophages were differentiated from peripheral blood monocytes by addition of 100 ng/ml M-CSF for 2-3 days in 5% FCS RPMI. Then, they were left uninfected, infected in serum-free medium with a control adenovirus encoding  $\beta$ -gal, infected with an adenovirus encoding wild-type MyD88 or infected with an adenovirus encoding dominant negative MyD88 (Adlpr). An moi of 100 was used. (a) After 48 h, supernatants were collected and assayed for TNF $\alpha$ , IL-6 and IL-8 cytokine production in the absence of any further stimulation. Cytokine production could be detected in cells encoding dominant negative MyD88 but not cells encoding wild-type MyD88 or control cells. This suggested that blocking MyD88 activity in macrophages, as in dendritic cells but not HSF or HUVEC, results in the activation of cells and the release of inflammatory cytokines. (b) At 0 h, 4h, 24 h and 48 h of expression, supernatants were collected and assayed by ELISA for TNF, IL-6 and IL-8. Only the results from cells encoding dominant negative MyD88 (MyD88-lpr) are shown as control cells or cells encoding wild-type MyD88 had background levels of cytokine production.

20

## MATERIALS AND METHODS

### 1. Reagents

Human recombinant GM-CSF and TNF $\alpha$  were kind gifts of Dr Glenn Larsen (GI) and Dr D Tracey (BASF), respectively. Human recombinant IL-4 was purchased from R&D Systems (Minneapolis, USA). PMA, LPS and Ionomycin were obtained from Sigma Chemical Co. (St Louis, USA). The proteasome inhibitor Cbz-Ile-Glu(O-tert-butyl-Ala-ceremal (PSI) was

The proteasome inhibitor Cbz-Ile-Glu(O-terr-butyl-Ala-ceremal (PSI) was obtained from Calbiochem (Nottingham, UK). M-CSF was obtained from the Genetics Institute (Boston, USA).

5 **2. Preparation of peripheral blood mononuclear cells**

Peripheral blood mononuclear cells (PBMC) were obtained by density centrifugation of leukopheresis residues from healthy volunteers (North London Blood Transfusion Service, Colindale, UK). Heparinised residues 10 were diluted 2X with HBSS and 25 ml were carefully layered over equal volumes of Ficoll-Hypaque lymphoprep (Nycomed, Oslo, Norway) in 50 ml sterile tubes prior to centrifugation for 30 minutes at 2000 rpm at room temperature. After centrifugation, the interface layer was collected and washed twice with HBSS (centrifuged for 10 minutes at 2000 rpm). PBMC 15 were then collected and resuspended in 30 ml of RPMI containing 5% FCS.

3. Isolation of peripheral blood T cells and monocytes and culture of HeLa cells

20 Peripheral blood T cells and monocytes were obtained from PBMC after cell cell separation in a Beckman JE6 elutriator. Elutriation was performed in RPMI containing 1% FCS (elutriation medium). Lymphocyte and monocyte purity was assessed by flow cytometry using fluorochrome-conjugated anti-human monoclonal antibodies against CD45, CD3, CD14 25 and CD19 (Becton Dickinson, Oxford, UK). T lymphocyte fractions typically contained ~80% CD3-expressing cells, ~6% CD19-expressing cells and <1% CD14-expressing cells. Monocyte fractions routinely consisted of >85% CD14-expressing cells, <0.5% CD19 cells and < 3% of

CD3-expressing cells. HeLa cells were maintained in 5% FCS, 1% penicillin/streptomycin DMEM.

#### 4. Differentiation of monocytes with M-CSF for adenoviral infection

5

To optimize adenoviral infection, freshly elutriated monocytes were cultured at  $1 \times 10^6$  cells/ml in 10 cm petri dishes (Falcon, UK) with 100 ng/ml of M-CSF (Genetics Institute, Boston, USA). After 2-3 days they were washed with PBS to remove non-adherent cells and the remaining 10 adherent monocytes were incubated with 10 ml of cell dissociation solution (Sigma, UK) for 1h at 37° C. The cell suspension was washed twice in RPMI containing 5% FCS and cell viability (90%) was assessed by trypan blue exclusion. Cells at this stage were 99% CD14 positive by FACS staining and were cultured at  $1 \times 10^6$ /ml, in 24-well or 48-well flat-bottomed 15 tissue culture plates (Falcon, UK) for further experiments.

#### 5. Differentiation of monocytes to dendritic cells

Freshly elutriated monocytes were cultured at  $1 \times 10^6$  cells/ml in 10 cm petri 20 dishes (Falcon, UK) in 5% FCS RPMI supplemented with 50 ng/ml GM-CSF and 10 ng/ml IL-4 for 5-6 days. At day 3, cytokines were replenished. This method presents several advantages as compared to differentiation of 25 dendritic cells directly from blood or bone marrow precursors. Besides being easy and giving high numbers of cells, it generates a homogenous population of cells with a stable "immature DC" phenotype. This phenotype can be pushed to maturation by addition of TNF $\alpha$  (10 ng/ml), LPS (100 ng/ml) or monocyte-conditioned medium (50% v/v) for a further 2-3 days to the DC.

## 6. Monocyte conditioned medium

Ig-coated plates (100mm, Falcon) were prepared immediately before use by the addition of 5 ml of human gamma-globulin (10 mg/ml, Sigma Chemical Co.) for 10 min. The plates were washed three times with RPMI 1640 medium (serum free) before use. Elutriated monocytes ( $3 \times 10^7$ ) were layered on the Ig-coated plates for 1 hr in 7 ml volumes. Non-adherent cells were washed off, and gamma-globulin adhered cells were incubated in fresh complete RPMI 1640 medium at 37° C for 24 hr.

10

## 7. Adenoviral vectors and their propagation

Recombinant, replication-deficient adenoviral vectors encoding E.coli  $\beta$ -galactosidase (Ad $\beta$ -gal) or having no insert (Ad0) were provided by Drs 15 A.Byrnes and M.Wood (Oxford University, UK). The GFP-expressing adenovirus (AdGFP) was generated by double recombination of AdTrack with AdEasy-1 adenoviral plasmid provided by Prof. B. Vogelstein (The Howard Huges Medical Institute, Baltimore, MD). AdMyD88wt and AdMyD88lpr were generated from plasmids provided by Dr Xu (University 20 of Texas, Southwestern) and Dr K. Burns (Lausanne, Switzerland). In particular, pAdTrackCMV was used for AdMEKK-1wt, whereas for AdMyD88wt and AdMyD88lpr, a pAdTrack.CMV vector derivative, termed AdTrack.CMVKS17, was used. pAdTrack.CMVKS17 was constructed by removing the EcoRI site of AdTrack.CMV as well as its 25 multiple cloning site (MCS), and by inserting the larger multiple cloning site of the vector pBCSK(+) (Stratagene). Recombinant viruses were generated in BJ5183 bacterial cells transformed by the heat-shock method with 1 $\mu$ g of linearised pAdTrack.CMV-MEKK1wt, AdTrack.CMVKS17-MyD88wt or AdTrack.CMVKS17-My88lpr constructs and 100ng of

replication-deficient adenoviral vector pAdEasy-1. Positive recombinant clones were selected through their resistance to kanamycin. Following selection, DNA extracted was used for virus propagation in the 293 human embryonic kidney cells. Viruses were purified by ultracentrifugation through two caesium chloride gradients; as described in He *et al.* (He T.C. et al. (1998). Science 281: 1509-12). Titres of viral stocks were determined by plaque assay, in HEK 293 cells, after exposure for 1 hour in serum free DMEM medium (Gibco BRL) and subsequently overlayed with an (1.5%) agarose/(2xDMEM with 4% FCS) mixture (v/v1:1) and incubated for 10-14 days .(He T.C. et al. (1998). Science 281: 1509-12).

### 9. Adenoviral infection of cells

M-CSF-differentiated macrophages and immature or mature dendritic cells were collected, counted and replated. Then, they were infected in serum-free RPMI with replication-deficient adenoviruses overexpressing the gene of interest. A multiplicity of infection of 100 for macrophages and immature DC, and 300, for mature DC, was used. After 2 h, the virus was removed and cells were cultured in complete medium for an additional 1-2 days to allow overexpression of the protein of interest. Then, they were used in further experiments.

### 10. Establishment of antigen-specific T cell lines

Green fluorescent protein was purchased from Clontech. To establish antigen-specific polyclonal T cell lines,  $1 \times 10^6$  PBMC/ml were cultured with antigen (1  $\mu$ g/ml for green fluorescent protein or 5  $\mu$ g/ml for tetanus toxoid) for 7 days and then with IL-2 at 20 ng/ml for another 10-14 days. Every 4 days IL-2 was replenished. This resulted in the expansion of antigen-

specific T cells and cell death of most other cell populations present in PBMC. After 17-21 days of culture, a restimulation step was included by culturing the T cells with autologous irradiated PBMC at a 1:1 ratio and fresh antigen in the absence of IL-2. After 4 days IL-2 was added for 5 another 10-14 days. This restimulation cycle was repeated at least 4 times before use of antigen-specific T cells in further experiments.

### **11. Proliferation assays of antigen-specific T cells**

10 To assess the specificity of antigen-specific T cell lines,  $1 \times 10^5$  of antigen-specific T cells were cultured with  $1 \times 10^5$  autologous irradiated PBMC and various concentrations of antigen in 96-well flat-bottomed microtiter plates. After 3 days, cells were pulsed with [<sup>3</sup>H]Thymidine overnight and harvested the following day.

15 To measure dendritic cell-induced antigen-specific T cell proliferation,  $1 \times 10^5$  antigen-specific T cells were cultured with graded doses of irradiated or mitomycin-treated dendritic cells that were unplussed, pulsed with antigen, uninfected or adenovirus-infected. [<sup>3</sup>H]-Thymidine incorporation 20 was measured after 2 days. All antigen-specific proliferation assays were done in triplicates.

### **12. Mixed lymphocyte reaction (MLR)**

25 To assay the immunostimulatory capacity of non-irradiated or irradiated (3000 rad from a <sup>137</sup>Cs source) DC, uninfected, adenovirus-infected, LPS-treated or monocyte-conditioned medium-treated DC were cultured in graded doses with  $1 \times 10^5$  of allogeneic elutriated T cells in quadruplicate in a 96-well flat-bottom microtiter plate (Falcon). Proliferation was measured

on day 5 by thymidine incorporation after a 16h pulse with [<sup>3</sup>H] thymidine (0.5 µCi/well; Amersham Life Science, UK).

### 13. Cytokine analysis

5

Cells were pre-treated with vehicle or 1 µM of PSI for 4 h, or infected with adenoviral vectors for 2 h. PSI-treated DC were then directly used in experiments whereas infected cells were further cultured for 2 days to allow overexpression of the relevant protein to occur. 24 h after stimulation of the 10 cells, culture supernatants were collected and kept frozen. Cytokine levels in cell culture supernatants were measured by standard 2 or 3 layer sandwich ELISA techniques using specific monoclonal and polyclonal antibodies for TNF $\alpha$ , IL-4, IL-6, IL-8, IL-12 and IFN $\gamma$ . Antibody pairs and standards for these assays have been purchased from Pharmingen, with the 15 exception of IL-12 reagents that were gifted from the Genetics Institute (Boston, USA).

### 14. Immunofluorescence staining and flow cytometry

20

For FACS staining, cells were first harvested. For adherent cells where surface receptors need to be intact, a warm 2% EDTA in PBS solution was used for 20 min at 37°C. After cells were in solution, they were washed once and then resuspended in ice-cold FACS washing buffer. All subsequent incubations were performed at 4°C. For each analysis, 5x10<sup>5</sup> 25 cells were incubated with the relevant antigen-specific antibody or isotype control for 30 min and then washed twice with FACS washing buffer. Cells were then examined by flow cytometry. Cells were ready for analysis on a FACScan flow cytometer (Becton and Dickinson) by using the CellQuest (Becton Dickinson). Directly conjugated monoclonal antibodies to HLA-

DR, HLA-A,B,C, CD80, CD86, CD3, CD14 and CD25 were purchased by Pharmingen, San Diego, USA).

### 15. Preparation of cytosolic protein extracts

5

Cytosolic extracts were prepared to investigate biochemical events involved in signal transduction by western blotting. Adherent cells were scraped from the tissue culture plate/flask into fresh PBS and harvested by centrifugation (13000g for 10 seconds at 4°C). Non-adherent cells were similarly pelleted 10 by centrifugation and washed once with fresh PBS. After discarding the supernatants, an appropriate quantity of ice-cold hypotonic lysis buffer (Whiteside S.T. et al (1992). Nucleic Acids Res 20:1531-8) was added, depending on the number of cells to be lysed (50-100 µl per 1x10<sup>6</sup> cells). After incubation on ice for 10 minutes, lysates were centrifuged (13000g, 5 15 minutes, 4°C) in order to remove nuclei and cell debris. The cleared lysates were then removed to fresh tubes, frozen and stored at -20°C for subsequent estimation of protein concentration and use in western blotting.

### 16. Preparation of nuclear protein extracts

20

Nuclear protein extracts were prepared to study the NF-κB activation and translocation from the cytosol to the nucleus and its DNA-binding ability. After lysis of cells in hypotonic lysis buffer (see section ), nuclei were pelleted by centrifugation (13000g for 5 minutes at 4°C), washed once in 25 hypotonic lysis buffer to remove contaminating cytosolic proteins, and then resuspended in hypertonic extraction buffer for 1-2 hours at 4°C under agitation. Hypotonic lysis buffer prevents leaching of proteins out of the nucleus during lysis, whereas hypertonic extraction buffer makes the nuclear membrane porous, allowing nuclear proteins to escape into solution.

After centrifugation (13000g for 10 minutes at 4°C) supernatants containing the nuclear protein were removed to fresh tubes and stored at -70°C. This method of nuclear extracts preparation is based on that of Whiteside S.T. et al (1992). Nucleic Acids Res 20:1531-8.

5

### 17. Immunoprecipitation

To immunoprecipitate IRAK, cytosolic extracts were incubated with 3 µg of anti-IRAK antibody for 1 h at 4°C under gentle shaking. Then, 50 µl of 50% slurry protein G sepharose (Amersham) were added and left for another 2 h shaking. Subsequently, IRAK bound to protein G sepharose was collected, washed four times, resuspended in Western Blot loading buffer, boiled for 5 min and then immediately used for Western blotting.

15 18. Protein concentration assay

Before using cytosolic or nuclear extracts in any further experimental procedure (e.g. western blotting, electrophoretic mobility shift assays), it was necessary to determine their protein concentration in order to ensure that equivalent amounts of protein were present in each sample. Protein concentrations were assessed by the Bradford assay. Briefly, 20 µl of appropriately diluted extracts were added in triplicates in a 96-well tissue culture plate along with 20 µl of a series of BSA concentrations (Sigma, UK) ranging from 10-1000 µg/ml to be used as a standard. 200 µl of Bradford reagent were then added to each well, and absorbance was measured at 595 nm in a spectrophotometer (Multiscan Bichromatic, Labsystems). From the linear standard curve formed by the range of BSA concentrations, protein amounts in the cytosolic and nuclear extracts were determined.

### 19. Western blotting and electrophoretic mobility shift assay

5 Cytosolic proteins were separated by SDS-PAGE on a 10% (w/v) polyacrylamide gel, followed by electrotransfer onto nitrocellulose membranes. I $\kappa$ B $\alpha$  and IRAK were detected by using antibodies purchased from Santa Cruz Biotechnology (Santa Cruz, USA) and Upstate Biotechnology (USA), respectively, whereas the phosphorylated forms of I $\kappa$ B $\alpha$ , p38 and p42/44 MAPK were detected by antibodies from New 10 England Biolabs.

## RESULTS

### 1. PSI inhibits the immunostimulatory function of DC.

15 PSI is an inhibitor of proteosome activity and as such is capable of inhibiting induced I $\kappa$ B degradation and subsequent NF- $\kappa$ B activation. We used PSI to examine the function of NF $\kappa$ B in dendritic cell (DC) activity particularly in relation to antigen presentation and activation of T cells. We have previously shown that PSI is capable of inhibiting NF $\kappa$ B activation at 20 concentrations up to 1  $\mu$ M. To test the effect of PSI on DC viability mature DC were incubated with concentrations of PSI, ranging from 0.1  $\mu$ M to 5  $\mu$ M. Concentrations of >5  $\mu$ M showed some toxicity (Figure 1), as judged by propidium iodide (PI) staining method and so functional studies were only performed over the 0.1 to 2  $\mu$ M range, using 1  $\mu$ M in most 25 experiments. To assess the role of NF $\kappa$ B in DC function, mature DC were incubated with 0.3  $\mu$ M, 0.5  $\mu$ M or 1  $\mu$ M PSI for 3 hours and the cells washed. As PSI is an activated peptide that binds irreversibly to the proteosomes, the function of the DC can be assessed over the 6 day period of the MLR despite the short period of drug exposure.

Exposure of T cells to PSI treated DC (PSI-DC) in an allogeneic MLR assay had profound effect on the response of the lymphocytes that was titratable with PSI concentration. It was found that while pretreatment of 5 DCs with PSI at 0.1  $\mu$ M had no detectable effect, 0.5  $\mu$ M and 1  $\mu$ M resulted in a failure of the T cells to proliferate in response to activation (Figure 2).

**2. PSI reduces the surface expression of molecules involved in antigen presentation.**

10 T cells in the MLR recognise HLA class II antigens, of which HLA-DR is the most abundant and so its expression was assessed, 6 days after PSI treatment. A minimal effect (by FACS) on DR was noted at 0.1  $\mu$  PSI, but a major reduction was found at 1  $\mu$ M (Figure 3). CD86 is the major costimulatory molecule expressed on DC, and its expression was also 15 reduced, to virtually background levels at 1  $\mu$ M PSI (Figure 3).

**3. Inhibited MLR with PSI treated dendritic cells is not rescued by IL-2 or anti CD28 antibody.**

There are two broad possibilities as to the mechanism of the low 20 proliferative response of T cells to PSI-DC. One is that these DC are not stimulatory, and the T cells are not responding for that reason. The second is that the T cells have been actively 'switched off' by processes of tolerance or active immune regulation. To begin to discriminate between these possibilities, we attempted to stimulate the T cells with IL-2, or anti 25 CD28 at concentrations (2-ng/ml. IL-2 or 10  $\mu$ g/ml. anti CD28).

The IL-2 or anti CD28 was added at the same time when T cells and DC were plated. Proliferation was assessed at day 6, and revealed that IL-2 had

a very slight effect at restoring proliferation, however this was independent of the number of DC and regardless of PSI treatment (Figure 4a).

5 The same degree of immunostimulation was seen with untreated DC (Figure 4b). Anti CD28 had no restorative effect, which had been expected in view of the downregulation of the major CD28 ligand CD86 by PSI (Figure 3). These results are consistent with multiple mechanisms and so led to further experiments.

10 **4. Inhibition of the DC induced MLR by DC pretreated with PSI.**

A means of detecting whether PSI-DC were generating inhibitory effects is to culture T cells with a mixture of PSI treated and untreated DC. If the PSI-DC were just non-stimulatory, PSI treated DC should have minimal effects on the proliferative response. However, it was found that the 15 presence of as little as  $\frac{1}{8}$  or  $\frac{1}{4}$  PSI-DC, resulted in a 3-5 fold reduction response, as judged from the slope of the proliferative response curves (Figure 5). Next we investigated whether exposure to PSI-DC would induce long term unresponsiveness in the T cells. T cells were exposed to normal or PSI-DC as previously described after which the T cells were 20 collected and were treated with a DC for a second time and the proliferative response measured (Figure 6). The T cells exposed to normal DC on both occasions responded and as expected T cells did not respond to two rounds of PSI-DC. However, T cells that had been stimulated with PSI-DC prior to normal DC also were unable to respond (Figure 6). This would indicate that 25 the effects of exposure to PSI-DC are prolonged and the T cells acquire a non-responsive or anergic state. As expected T cells exposed to PSI-DC on the second round after normal DC also failed to proliferate.

**5. Cell surface antigen analysis of T lymphocytes exposed to PSI treated dendritic cells.**

To probe into the mechanism of the effect of PSI treated DC, we analysed T lymphocyte after 6 days cultures. As anticipated the yields of T cells were 5 lower. Cell surface expression of CD3 was reduced. Most dramatic, however, was the marked diminution of CD25 expression, which was virtually abolished compared to controls (Figure 7).

10 Expression of molecules involved in cell surface adhesion, such as CD11a (LFA-1) and one of its receptors ICAM-1 CD54 was analysed. Both were reduced on PSI treated lymphocytes with CD54 reduced to a degree similar to CD3 whereas CD11a expression was only marginally reduced (Figure 7).

**15 6. Exposure to T cells to PSI-DC results in the production of IL-4 but not IL-2 or IFN $\gamma$**

The production of cytokines is one of the key responses by T cells to 20 stimulation by DC with IL-2, IFN $\gamma$  and IL-4 being expressed (Figure 8). We therefore investigated what type of response occurs with exposure to PSI-DC. IL-2 and the key Th1 cytokine, IFN $\gamma$  were not produced in response to PSI-DC. However, the production of IL-4 was unaffected. This data would suggest that PSI-DC are capable of delivery some signals to T cells. This would support our prior observation that PSI-DC induce a type of unresponsiveness state in the T cells which is thought to require an active signal.

25

**7. DC production of TNF but not IL-8 is inhibited by PSI.**

We also investigated the effect of PSI on cytokine produced by the DC following on MLR. TNF and, to a lesser extent, IL-6 expression was inhibited from PSI-DC during the MLR. In contrast IL-8 production was

unaffected (Figure 9). Like results on the T cell this shows the discriminatory nature of PSI treatment, and indicates that NF $\kappa$ B has a role in TNF and IL-6 expression but not that of IL-8.

5     **8. Activating DC with MEKK1 results in enhanced MLR response.**  
Since inhibition of NF $\kappa$ B inhibits the function of DC, the effect of potentially activating DC using NF $\kappa$ B stimulating MEKK was investigated. Activating encoding MEKK1 was used to infect DC at m.o.i. of 150:1. When used in an MLR such MEKK1 DC was 4-fold more active than  
10    normal DC (Figure 10).

9.     **Myd881pr activates NF- $\kappa$ B**  
We have found that a potent inducer of NF- $\kappa$ B is a mutein of Myd88 that contains a deletion of the first 53 amino acids and a point mutation  
15    Phe56Asn termed Myd881pr. Myd881pr is normally inhibiting to Toll related receptor signalling, for example, IL-1 receptors (1). However, we have observed that introduction of Myd881pr, by adenoviral vectors, into immature DC induces a potent activation of nuclear NF- $\kappa$ B activity that is detectable six hours after infection with Admyd88 and more strongly, at 24  
20    hours post-infection (Figure 11).

10.    **Myd881pr induces TNF production by immature DC**  
As with MEKK1, we were interested to see if Myd881pr would also activate DC function. Infection of immature DC with AdMyd881pr, 25 resulted in the spontaneous production of TNF by the cells 24 hours post infection. Moreover, Myd881pr had no inhibiting effect on LPS-induced TNF production. Myd88wt did not induce TNF production in DC (Figure 12)

**11. Myd881pr enhances antigen presentation by DC**

Since inhibition of NF- $\kappa$ B inhibits the function of DC, the effect of potently activating DC using the NF- $\kappa$ B stimulating Myd881pr was investigated. Immature DC were infected with AdMyd881pr (that also expresses GFP), Ad0 or AdGFP (Green Fluorescent Protein). After 24 hours, various concentrations of infected DC were cultured with  $2 \times 10^4$  GFP antigen-specific T cells and response measured as proliferation of the T cells at three days. Delivery of GFP to dendritic cells induced an antigen specific T cell proliferation that was enhanced by Myd881pr (Figure 14). This result is in agreement with activation of NF- $\kappa$ B and TNF production by Myd881pr shown in the previous figures (Figures 11 and 12).

**12. Myd881pr also enhances DC induced allogenic mixed lymphocyte reaction (MLR)**

Another test of the effect of activity NF- $\kappa$ B function on DC was to investigate the MLR response. Immature DC were infected with Ad0 and Admyd881pr and, after 48 hours, graded doses of the infected DC were cultured with  $10^5$  allogenic T cells and responses measured as proliferation after six days of culture. Infection with AdMyd881pr enhanced the MLR response over that of Ad0 or uninfected cells. This was most notable at lower DC numbers where the response of the controls was only equal to T cells only, where the Myd881pr expressing DC response was higher (Figure 15).

**25 13. Myd881pr expression enhances the expression of costimulating molecules CD80 and CD86.**

The expression of the cell surface molecules CD80 and CD86 are important to the antigen presenting function of DC. In figure 16, we show that expression of Myd881pr in DC (by adenoviral infection) enhanced the

expression of both CD80 and CD86, when compared with uninfected DC's, or cells infected with control virus.

14. **Myd88lpr also activates other signalling molecules in addition to**  
5 **NF-κB.**

We have shown that Myd88lpr is a potent inducer of NF-κB. We also observed that this molecule could activate other signalling pathways, this time in macrophages, such as p38 MAPK, a kinase known to be involved in cell mechanisms such as the control of cytokine expression (Figure 17).

10 Moreover, in macrophages, Myd88lpr also activated IRAK1, a key element of TLR and IL-1R signalling mechanisms (Figure 18).

## REFERENCES

15 1. Burns, K., F. Martinon, C. Esslinger, H. Pahl, P. Schneider, J.L. Bodmer, F. Di Marco, L. French, and J. Tschopp. 1998. MyD88, an adapter protein involved in interleukin-1 signaling. *J Biol Chem* 273, no. 20:12203.

20

## DISCUSSION

Treatment of DC with PSI, a proteasome inhibitor, at concentrations capable of blocking the induction of NFκB, was shown to reduce the 25 proliferative response in the MLR. This suggests that NFκB function is involved in the stimulation of unprimed T cells in the MLR. As the specificity of PSI is for the proteasome, it hence could potentially affect the function of other transcription factors, although this was not reported in the original publications describing the action of this drug (Traenckner *et al*

(1994) EMBO J. **13**, 5433-5441; Traenckner & Baeuerle (1995) J. Cell Sci. Suppl. **19**, 79-84; and Haas *et al* (1998) J. Leukoc. Biol. **63**, 395-404). Other, independent experiments to verify the role of NF $\kappa$ B using other approaches will be needed, and we have initiated studies using infection of

5 DC with an adenovirus overexpressing I $\kappa$ B $\alpha$  under the control of the CMV promoter. This I $\kappa$ B $\alpha$  overexpression inhibits NF $\kappa$ B, and also inhibits the antigen presenting function of dendritic cells (Yoshimura *et al.*, unpublished data), compatible with the data presented here.

10 The mechanism of PSI treated DC reduced immunogenicity was evaluated at different levels, and it turned out that multiple aspects of antigen presenting cell function in DC were downregulated. First, the effects on the expression of cell surface molecules by which DC stimulate T cells has been studied, and a marked reduction in the expression of HLA-DR and

15 CD86, both molecules important for both antigen recognition and CD28 activation, was found. Reductions in DC derived cytokines such as IL-12 and TNF $\alpha$ , both known to be important in the early activation of T cells, were also found. In contrast the production of other cytokines such as IL-6 or IL-8 was not changed in T cell/DC cocultures. These results indicate that

20 PSI treated DC have reduced expression of all three major classes of molecules involved in antigen presentation – the target of T cell recognition (HLA-DR) the costimulatory molecules (CD86), as well as immunostimulatory cytokines (IL-12 and TNF $\alpha$ ).

25 Further questions as to the mechanism of the lack of the T cell proliferative response were addressed. It could simply be due to lack of immunogenicity of the DC, or alternatively it could be due to the induction of a form of immunological tolerance or of immune regulation. The mechanism was analysed further by coculture experiments, adding PSI treated DC to

untreated DC, and analysing the effect of the mixture on unprimed T cells in the MLR. It was found that if as few as  $1/8$  (12.5%) PSI treated DC are added to untreated DC there is a significant reduction in the proliferation dose response curve, equivalent to 3-5 fold less active DC. This result, as 5 well as the fact that IL-2 and anti CD28 failed to stimulate these T cells (data not shown), indicates that there is an inhibitory (immunomodulatory) effect of PSI treated DC on T cell function. Furthermore, exposure of T cells to PSI pretreated DC induced profound changes in the expression of T cell surface markers, analyzed on day 6 of coculture: there was reduced 10 expression of CD3, virtually abolished CD25, and some reduction in ICAM-1 and LFA-1. Similar effects have been reported in a variety of tolerance models Zanders *et al* (1983) *Nature* **303**, 625-627; Zanders *et al* (1985) *J. Immunol.* **15**, 302-305; Park *et al* (1997) *Eur. J. Immunol.* **15**, 302-305; and Waldmann & Cubbold (1998) *Ann. Rev. Immunol.* **16**, 619- 15 644 and so we asked whether PSI treated DC induced immunological tolerance. This was assessed by first exposing allogeneic T cells to PSI treated DC for 2 days, and then removing them, by panning with anti CD83 and anti CD86. The T cells were then exposed for 4 days to normal DC/or PSI treated DC from the same donor, and their lack of response is evidence 20 that at least 'long lasting' (4-6 day) immunological tolerance has been induced. The formal definition of tolerance includes 'antigen specificity', that could not be formally tested in this kind of experiment, but it has later been verified in an independent series of experiments using T cell lines responsive to a soluble antigen, tetanus toxoid (Calder *et al.*, unpublished 25 data). However, the term 'immunological tolerance' in this context is an appropriate one, since rechallenge was performed with DC from the same donor.

In another set of experiments, the function of the T cells exposed to PSI treated DC was evaluated further. The T cell cytokine production was markedly altered. Thus IL-2 production was inhibited by more than 90%, as was IFN $\gamma$  production, findings that are also compatible with the induction 5 of tolerance. IL-2 and IFN $\gamma$  are 'Th1' cytokines, as it was of interest that the expression of the 'Th2' cytokine, IL-4 was not changed. This suggests that the immunosuppressive effect/tolerance induction induced by PSI treated DC may be restricted to the Th1 subset. Further studies with purified Th1 and Th2 T cells are needed to address this point.

10

The studies reported here, and other experiments using an adenovirus overexpressing the endogenous NF $\kappa$ B inhibitor I $\kappa$ B $\alpha$  (Yoshimura et al., unpublished data), indicate that NF $\kappa$ B has an important role in the regulation of antigen presentation. This agrees well with the earlier finding 15 that NF $\kappa$ B is essential for DC maturation Rescizno *et al* (1998) *J. Exp. Med* **188**, 2175-2180. It is also consistent with the concept that NF $\kappa$ B is the major mechanism by which innate immunity is translated into adaptive immunity. The so called 'danger signal', which activates the immune system Matzinger (1994) *Ann. Rev. Immunol* **12**, 991-1045; Janeway *et al* 20 (1996) *Curr. Biol.* **6**, 519-522, activated via a wide variety of microbial or other noxious agents thus appears to involve the activation of NF $\kappa$ B. This has already been established for LPS that requires TLR4 to induce NF $\kappa$ B activation Chow *et al* (1999) *J. Biol. Chem.* **274**, 10689-10692.

25 In the context of regulation of antigen presentation it is noteworthy that all 3 aspects, expression of target for T cells (MHC), costimulatory molecules (CD86) as well as inducing cytokines (IL-12, TNF $\alpha$ ) are all regulated coordinately by NF $\kappa$ B. This leads to an obvious prediction, that drugs that

block NF $\kappa$ B (such as PSI) may be useful immunosuppressive agents *in vivo*, depending clearly on their toxicity profile. PSI is likely to be too toxic for systemic use might nevertheless be useful for perfusing target organs, such as kidneys, to block APC function prior to transplantation. An interesting 5 corollary of this work is that the deliberate activation of NF $\kappa$ B might provide a good strategy for a useful adjuvant effect for vaccines. Experiments to test that hypothesis are under way.

Further studies are underway to further analyse the exact mechanism by 10 which PSI treated DC influence T cell function:

1. Blocking NF- $\kappa$ B in antigen presenting cells is inhibitory to T cell function, using PSI or other proteosome inhibitors, e.g. or other inhibitors of NF- $\kappa$ B, e.g. cDNA inhibitors such as I $\kappa$ B, antisense to NF- $\kappa$ B constitutes 15 drug inhibitors such as
2. Blocking NF- $\kappa$ B in DC induces tolerance in T cells
3. Use of NF- $\kappa$ B inhibitors in ) autoimmunity  
20 ) transplantation  
 ) allergy
4. Corollary - if NF- $\kappa$ B inhibition blocks antigen presentation and promotes tolerance, then NF- $\kappa$ B stimulation will upregulate antigen 25 presentation. This can be achieved in a number of possible ways, activating pathways which stimulate NF- $\kappa$ B, in order to augment vaccination. These include using adenoviruses or other gene transfer of MEKK1, NIK, IKK2, dominant negative mutants of MyD88, TRAF2, TRAF6. These sequences could be incorporated into the same genetic construct as that encoding the

antigen to which immunisation is desired. NF- $\kappa$ B stimulation may also be useful in modulating the immune response in an allergic patient to alter the TH1:TH2 response balance towards a TH1 response.

5 We believe that the results show that PSI produces an anergic state in DCs. That is the drug induces a long term state of non-responsiveness of the DCs to antigens.

10 The corollary to the above observations is that by activating an intracellular signalling pathway, such as NF- $\kappa$ B, in DC, one would activate the cell and enhance antigen presenting function. We tested this using NF- $\kappa$ B activating intracellular signalling molecules MEKK1 and Myd881pr. MEKK1 has been previously described as an activator of NF- $\kappa$ B amongst other pathways and the introduction of MEKK1 into DC using adenoviral vectors induced 15 activation of DC function as measured by MLR.

20 We also observed that a mutein of Myd88, Myd881pr, normally an inhibitor of signalling by TLR and IL-1 receptors, also activated NF- $\kappa$ B in DC. When expressed in DC, Myd881pr enhanced DC antigen present function as measured by MLR, or using antigen specific T cells as well as inducing cytokine production. These results open the possibility that when 25 associated with antigens, intracellular signalling molecules, such as NF- $\kappa$ B, can act as powerful adjuvants. This could provide a new approach to vaccine design. The fact that Myd881pr also activates p38 MAPK would imply that other signalling molecules that activate DC could also be used for this purpose.

**CLAIMS**

1. A method of inhibiting antigen presentation or inducing an anergic response in a mammal, such as a human, comprising administering a pharmaceutically-effective dose of an intracellular inhibitor of APC, such as DC, function.  
5
2. A method of inhibiting antigen presentation or inducing an anergic response in a mammal, such as a human, comprising administering a pharmaceutically-effective dose of an NF- $\kappa$ B inhibitor.  
10
3. A method of treating an allergy or an autoimmune disease comprising administering a pharmaceutically-effective dose of an intracellular inhibitor of APC, such as DC, function to induce an anergic response in a mammal.  
15
4. A method of treating an autoimmune disease comprising administering a pharmaceutically-effective dose of an NF- $\kappa$ B inhibitor to induce an anergic response in a mammal.  
20
5. A method of preventing transplant rejection in a mammal, such as a human, comprising administering a pharmaceutically-effective dose of an intracellular inhibitor of APC, such as DC, function to induce an anergic response in a mammal.  
25
6. A method of preventing transplant rejection in a mammal, such as a human, comprising administering a pharmaceutically-effective dose of an NF- $\kappa$ B inhibitor to induce an anergic response in a mammal.

7. A method, according to any one of claims 2, 4 or 6, comprising administering a vector comprising nucleic acid encoding an NF- $\kappa$ B inhibitor operatively linked to regulatory elements necessary for expression of said nucleic acid.

5

8. A method according to claim 7, wherein the vector is an adenovirus or lentivirus.

9. NF- $\kappa$ B inhibitor for use as a medicament.

10

10. NF- $\kappa$ B inhibitor for use in inducing an anergic response or inhibiting antigen presentation in a mammal.

15

11. NF- $\kappa$ B inhibitor for use in treating autoimmune disease or allergy by inducing an anergic response.

12. NF- $\kappa$ B inhibitor for use to inhibit the rejection of transplanted tissue by inducing an anergic response.

20

13. Use of NF- $\kappa$ B inhibitor the manufacture of a medicament to induce an anergic response.

14. A method or inhibitor according to any preceding claim wherein the inhibitor is I $\kappa$ B $\alpha$  or PSI or an IKK2 dominant negative mutant.

25

15. A method or inhibitor according to any one of claims 1 - 10, wherein the inhibitor is anti-sense nucleic acid effective against at least a portion of an NF- $\kappa$ B.

16. A method or inhibitor according to claim 15 wherein the anti-sense nucleic acid is effective against Rel B.
17. A method or an inhibitor according to any preceding claim, wherein the inhibitor is encoded by nucleic acid in a vector, the vector additionally comprising regulatory elements operatively linked to said nucleic acid.
18. A method or an inhibitor according to claim 17, wherein the inhibitor is an Fv fragment of an antibody.
- 10 19. A method or an inhibitor, according to any one of claims 1-11, 14 or 15 wherein the inhibitor is an antibody or an effective fragment thereof, or a cDNA encoding an antibody or an effective fragment thereof, capable of binding NF- $\kappa$ B or a fragment thereof.
- 15 20. A method or an inhibitor according to claim 19, wherein the antibody is an anti-Rel B antibody or an effective fragment thereof or cDNA encoding Rel B or an effective fragment thereof.
- 20 21. A method of stimulating antigen presentation or of stimulating an immune response in a mammal, such as a human, comprising administering a pharmaceutically effective amount of an intracellular inducer of APC, such as DC, function.
- 25 22. A method of stimulating antigen presentation or of stimulating an immune response in a mammal, such as a human, comprising administering a pharmaceutically effective amount of an NF- $\kappa$ B inducer.

23. A method according to claim 18 for treating an infectious disease or a cancer.

24. An NF-κB inducer for use as a medicament.

5

25. An NF-κB inducer for use to stimulate an immune response.

26. An NF-κB inducer according to claim 25 for use as an anti-infectious disease agent or anti-cancer agent.

10

27. An NF-κB inducer for use in the manufacture of a medicament to treat infectious disease or cancer or a condition characterised by aberrant types or aberrantly high levels of harmful molecules in the body.

15

28. A method or NF-κB inducer, according to any one of claims 22 to 27, wherein the inducer is selected from MEKK1, NIK, IKK2, TRAF2, TRAF5, TRAF6, TAK, a dominant negative mutant of Myd88, TP L-2, IRAK, IKK5, Toll receptors and Rel B, or fragments or muteins thereof which are capable of inducing NF-κB.

20

29. A method or NF-κB inducer according to any one of claims 18-23 wherein the NF-κB inducer is encoded by nucleic acid within a vector, the vector additionally comprising regulatory elements operatively linked to said nucleic acid and necessary for expression of said nucleic acid.

25

30. A method or NF-κB inducer of claim 29, wherein the vector is an adenovirus or lentivirus.

31. A method or NF- $\kappa$ B inducer according to any one of claims 18-24, wherein the inducer is in the form of a DNA vaccine.

32. A method of inhibiting the maturation and activation of APCs, such as dendritic cells *in vivo* or *in vitro*, comprising administering an effective amount of an inhibitor of NF- $\kappa$ B.

33. A method of stimulating the maturation and activation of APCs, such as dendritic cells *in vivo* or *in vitro*, comprising administering an effective amount or an inducer of NF- $\kappa$ B.

34. The method, inhibitor, inducer or use of any of the preceding claims wherein the mammal, such as a human, is administered an antigenic molecule or polynucleotide encoding an antigenic molecule.

35. The method, inhibitor, inducer or use of any of the preceding claims wherein the inhibitor or inducer is targeted to APCs such as dendritic cells or precursors thereof.

36. The method, inhibitor, inducer or use of any of the preceding claims wherein APCs, such as dendritic cells or precursors thereof are exposed to the inhibitor or inducer *in vitro* and introduced into the mammal.

37. A molecule comprising (1) a portion (modulating portion) comprising or encoding an intracellular modulator, for example intracellular inhibitor or intracellular enhancer, of APC, such as DC, function and (2) a portion comprising or encoding an antigenic molecule (antigenic portion).

38. A polynucleotide encoding an antigenic molecule and an enhancer of APC, such as DC, function.

39. The molecule of claim 33 or polynucleotide of claim 34 wherein the 5 enhancer of APC, such as DC, function is a NF- $\kappa$ B inducer.

40. A kit of parts or composition of chimaeric molecule, comprising (1) an intracellular modulator, for example intracellular inhibitor or intracellular enhancer, of APC, such as DC function and (2) an antigenic portion 10 comprising or encoding an antigenic molecule.

41. A kit of parts or composition or a chimaeric molecule, comprising (1) a modulating portion comprising or encoding a NF- $\kappa$ B inhibitor or inducer and (2) an antigenic portion comprising or encoding an antigenic 15 molecule.

42. The method, inhibitor, inducer or use of claim 34 or molecule, polynucleotide, kit of parts, composition or chimaeric molecule of any one of claims 37 to 41 wherein the antigenic molecule comprises an epitope 20 present on transformed or cancerous cells or on a pathogenic organism, or on a cell infected by a pathogenic organism, or a polypeptide expressed in a pathologic condition such as Alzheimer's disease or a spongiform encephalopathy.

25 43. A vaccine effective against cancer, or cancer or tumour cells, or against a pathogenic organism or cell infected with a pathogenic organism, or a disease characterised by the expression of a polypeptide in a pathologic condition such as Alzheimer's disease or a spongiform encephalopathy

comprising an effective amount of an NF- $\kappa$ B inducer or polynucleotide encoding an NF- $\kappa$ B inducer.

44. The vaccine of claim 43 further comprising an antigen or 5 polynucleotide encoding an antigen, having an epitope present on the cancer or tumour cells, or the pathogenic organism or cell infected with a pathogenic organism or present in a polypeptide associated with a pathologic condition.

10 45. The vaccine of claim 43 or 44 wherein the vaccine is a nucleic acid vaccine.

15 46. A pharmaceutical composition comprising a NF- $\kappa$ B inducer, NF- $\kappa$ B inhibitor, vaccine, molecule, polynucleotide, kit of parts, composition or chimaeric molecule of any of the preceding claims and a pharmaceutically acceptable carrier.

47. A vaccine, molecule, polynucleotide, kit of parts, composition or chimaeric molecule of any one of claims 37 to 46 for use in medicine.

20 48. Use of a vaccine, molecule, polynucleotide, kit of parts, composition or chimaeric molecule of any one of claims 37 to 46 in the manufacture of a medicament for the treatment of a patient in need of modulation of antigen presentation.

25 49. A method of killing target cells in a patient which target cells aberrantly express a first epitope, the method comprising the steps of (1) obtaining APCs, such as dendritic cells, from said patients; (2) contacting said APCs, such as dendritic cells, with an enhancer of APC, such as DC,

function *ex vivo*; (3) optionally contacting said cells, with the said epitope or with a polynucleotide or expression vector encoding the said epitope and (4) reintroducing the so treated APCs, such as dendritic cells, into the patient.

5

50. A method of killing target cells in a patient which target cells aberrantly express a first epitope, the method comprising the steps of (1) obtaining APCs, such as dendritic cells, from said patient; (2) contacting said APCs, such as dendritic cells, with a NF- $\kappa$ B inducer *ex vivo*; (3) 10 optionally contacting said cells with the said epitope or with a polynucleotide or expression vector encoding the said epitope and (4) reintroducing the so treated APCs, such as dendritic cells, into the patient.

51. A method of killing target cells in a patient according to claims 49 and 15 50 wherein the target cells are cancer cells.

52. Use of an NF- $\kappa$ B inhibitor or nucleic acid encoding an NF- $\kappa$ B inhibitor in the manufacture of a medicament for treatment of a mammal in need or induction of an anergic response.

20

53. The use of claim 52 wherein the mammal has an autoimmune disease or an allergy or is in need of prevention of transplant rejection.

25

54. Use of an NF- $\kappa$ B inducer or nucleic acid encoding an NF- $\kappa$ B inducer in the manufacture of a medicament for treatment of a mammal in need of stimulation of an immune response and/or in need of treatment of infectious disease or cancer or a disease associated with production of a pathogenic polypeptide such as Alzheimer's disease or a spongiform encephalopathy.

55. Use of an inhibitor of NF-κB or nucleic acid encoding an inhibitor of NF-κB in the manufacture of a medicament for treatment of a patient in need of inhibition of the maturation and activation of APCs, such as dendritic cells.

5

56. Use of an inducer of NF-κB in the manufacture of a medicament for treatment of a patient in need of stimulation of the maturation and activation of APCs, such as dendritic cells.

10 57. The molecule of claim 37 or polynucleotide of claim 38 wherein the modulator, for example enhancer of APC, such as DC, function is an intracellular signalling molecule.




Figure 1 (page 1 of 2)




Figure 1 (page 2 of 2)




Figure 2

## Effect of PSI on the expression of surface antigens







Figure 3

Figure 4 (page 1 of 2)








7/26

SUBSTITUTE SHEET (RULE 26)








Figure 7 (page 1 of 2)

Figure 7



Reduced expression of surface antigens on allo-lymphocytes by PSI pre-treated DC


Figure 7 (page 2 of 2)



11/26

SUBSTITUTE SHEET (RULE 26)

Figure 8 (page 1 of 3)



12/26

Figure 8 (page 2 of 3)




Figure 8 (page 3 of 3)






Figure 9 (page 1 of 2)

Figure 9 (page 2 of 2)






Figure 10

## Overexpression of MyD88-lpr intoimmature dendritic cells induces NF-κB activation





Figure 11

Figure 12

Effect of overexpression for 24h of MyD88 WT and DN forms on immature dendritic cells



18/26

Overexpression of wild-type MyD88 abrogates the  
Adlpr-induced TNF $\alpha$  production in dendritic cells




Figure 13

Figure 14

GFP-specific T cell proliferation is increased when MyD88lpr is overexpressed into DC




Figure 15

## Allogeneic MLR





Figure 16

Overexpression of MyD88lpr enhances expression of CD80 and CD86 in immature DC



## Activation of p38 MAPK in human macrophages by blocking MyD88




Figure 17

## (a) Macrophages


Uninf.    $\beta$ -gal   MyD88wt   MyD88lpr

+LPS

+LPS

+LPS

+LPS



## (b) HE LA




Figure 18

**Overexpression of dominant negative MyD88  
induces I $\kappa$ B $\alpha$  phosphorylation in human  
macrophages**




Figure 19

**Macrophage cytokine production after 2 days  
overexpression**

	TNF $\alpha$ (pg/ml)	IL-6 (pg/ml)	IL-8 (pg/ml)
Uninfected	<20	<50	1000-3000
Ad0	<20	<50	1000-3000
AdMyD88wt	<20	<50	1000-3000
AdMyD88-lpr	40-500 (max 1000)	500-1500	10000-15000

**Time-course of macrophage cytokine production after  
infection with AdMyD88-lpr**

	TNF $\alpha$ (pg/ml)	IL-6 (pg/ml)	IL-8 (pg/ml)
0h	<20	<70	1700
4h	<20	<70	2200
24h	170	490	14200
48h	70	750	13500

Figure 20

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number  
WO 01/47543 A3(51) International Patent Classification<sup>7</sup>: A61K 38/16. 48/00, C07K 14/00, C12N 15/62, A61P 37/00, 37/04, 37/06, 37/08, 35/00

(74) Agent: MILES, John, S.; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD, United Kingdom (GB).

(21) International Application Number: PCT/GB00/04925

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 22 December 2000 (22.12.2000)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

**Published:**

— with international search report

(26) Publication Language: English

(88) Date of publication of the international search report: 17 January 2002

(30) Priority Data: 9930616.9 24 December 1999 (24.12.1999) GB

(71) Applicant (for all designated States except US): THE MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY TRUST [GB/GB]; 1 Aspenlea Road, Hammersmith, London W6 8LH (GB).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): FOXWELL, Brian [GB/GB]; Kennedy Institute of Rheumatology Division, Imperial College School of Medicine, 1 Aspenlea Road, Hammersmith, London W6 8LH (GB). FELDMANN, Marc [AU/GB]; Kennedy Institute of Rheumatology Division, Imperial College School of Medicine, 1 Aspenlea Road, Hammersmith, London W6 8LH (GB).

A3

WO 01/47543

(54) Title: ACTIVATION AND INHIBITION OF THE IMMUNE SYSTEM

(57) Abstract: Activation of the immune response by NF- $\kappa$ B inducers, induction of an anergic response by NF- $\kappa$ B inhibitors and the inhibition and activation of immune response by the administration of an activator or inhibitor of NF- $\kappa$ B is disclosed. Examples of NF- $\kappa$ B inhibitors include I $\kappa$ B $\alpha$ , PSI, a nucleotide sequence encoding I $\kappa$ B $\alpha$  anti-sense nucleic acid encoding an NF- $\kappa$ B sequence, such as Rel B, and anti-NF- $\kappa$ B antibodies. Examples of NF- $\kappa$ B inducers include NIK, MEKK, IKK2, TFRRF2 and Rel B. Also disclosed are vectors encoding inducers and inhibitors of NF- $\kappa$ B, for example adenoviral vectors.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04925

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7	A61K38/16	A61K48/00	C07K14/00	C12N15/62	A61P31 00
	A61P37/04	A61P37/06	A61P37/08	A61P35/00	

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE, MEDLINE, CANCERLIT

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 897 009 A (SMITHKLINE BEECHAM PLC) 17 February 1999 (1999-02-17)  * page 2 lines 5-29, page 6 lines 30-53, page 8 lines 45-51, page 10 lines 33-38 * ---	22-27, 29,30, 43,46, 47,54,57
X	WO 99 42137 A (BROMLEY PETER) 26 August 1999 (1999-08-26)	22-30, 43,46, 47,54,57
Y	* claims and page 12 lines 35-38 *	22-31, 37-47, 49-51, 54,57
	---	
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

13 July 2001

23.07.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Merckling, V

**INTERNATIONAL SEARCH REPORT**

International Application No.

PCT/GB 00/04925

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 08955 A (SIGNAL PHARM INC) 5 March 1998 (1998-03-05)  * page 3 line 20 to page 4 line 2, page 15 line 26, page 19 line 15 to page 21 line 10 *	22-31, 43, 45-47, 54,57
X	EP 0 894 855 A (SMITHKLINE BEECHAM CORP) 3 February 1999 (1999-02-03)  ---	2,3, 5-13,17, 18, 22-31, 43, 45-47, 54,57
Y	* page 2 lines 12-21, page 10, section [0062], claim 14 *	14,15
X	WO 97 37016 A (BOLDIN MARK ;METT IGOR (IL); WALLACH DAVID (IL); MALININ NIKOLAI () 9 October 1997 (1997-10-09)  * page 4, page 6, pages 29-30, claims 9,19,32-33 and 36 *	22-31, 43, 45-47, 54,57
X	US 5 854 043 A (JOHNSON GARY L) 29 December 1998 (1998-12-29)  * col. 54 line 6 to col. 55 line 15 *	22-30, 43,46, 47,54,57
Y	WO 98 28424 A (IMMUNEX CORP) 2 July 1998 (1998-07-02)  * pages 2 and 4, example 13 *	22-31, 37-47, 49-51, 54,57
X	WO 96 25666 A (UNIV YALE) 22 August 1996 (1996-08-22)  ---	2-4, 7-11,13, 17-19, 46,47, 53,57
Y	* see abstract, pages 9,14-15,26-29 and 46, claims 28-29 *	14,15
X	WO 99 65449 A (SMITHKLINE BEECHAM CORP ;CHABOT FLETCHER MARIE C (US); CALLAHAN JA) 23 December 1999 (1999-12-23) * see abstract, claims 5 and 18 *	2,3,5,6, 9,13,46, 47,57 15
	---	-/-

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04925

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 06692 A (CELGENE CORP ;MULLER GEORGE W (US); SHIRE MARY (US)) 19 February 1998 (1998-02-19) * see abstract, pages 5-6 *	2,3,5,6, 9-13,46, 47,57 15
X	--- EP 0 779 361 A (HOFFMANN LA ROCHE) 18 June 1997 (1997-06-18)	2,3, 5-14,17, 18,46, 47,57
Y	* see abstract, page 3 line 47, example 8 and claims 1,6 and 18 *	14,15
X	--- WO 99 06009 A (ELFORD HOWARD L) 11 February 1999 (1999-02-11)	2,3,5,6, 9-13,46, 47,57
Y	* see claims 1,9 and 10 *	15
Y	--- WO 99 27112 A (MUZIO MARTA ;HUMAN GENOME SCIENCES INC (US); FENG PING (US); NI JI) 3 June 1999 (1999-06-03) * see abstract, pages 9 and 26-27, claim 18 *	22-31, 43, 45-47, 54,57
	-----	

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 00/04925

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 1-8, 14-23, 28-36, 42, 49-51 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
2-20,22-31,37-47,49-51,53-54,57
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.:

1,2-3\*,13\*,21,22\*,27\*,32-33\*,37-38\*,40\*,47\*,48,49\*,52,54\*,55-56

NB : \* means that the claim was searched partially

Present claims 1, 21, 48, 52 and 55-56 relate to methods defined by reference to desirable characteristics or properties, namely :

- a) intracellular inhibitor (respectively inducer) of APC, such as DC function (cl. 1 and 21), or
- b) treatment of a patient in need of modulation of antigen presentation / treatment of a mammal in need of induction of an anergic response / treatment of a patient in need of inhibition (respectively stimulation) of the maturation and activation of DC (cl. 48, 52, 55-56).

The claims cover all methods having these characteristics or properties, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the methods by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the methods comprising the use of c) for the treatment of d), defined as follows :

- c) inhibitors or inducers of NF-kappaB
- d) prevention of transplant rejection, autoimmune diseases, allergy (as in claims 5 and 11 for example), infectious diseases, cancer (as in claim 27 for example).

In a similar manner, claims 2-3, 13, 22, 27, 32-33, 37-38, 40, 47, 49 and 54 were searched partially. All of them contain an unclear and ambiguous definition of the compounds as in a) and/or of the disease to be treated as in b). For all of these claims, the search was limited to compounds as defined in c) and diseases as defined in d).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 2-3 (part), 4, 7-11 (part), 13-20 (part), 37 (part), 40-42 (part), 46-47 (part), 53 (part), 57 (part)

Use of NF-kappaB inhibitors for treating autoimmune diseases.

2. Claims: 2-3 (part), 9-11 (part), 13-20 (part), 37 (part), 40-42 (part), 46-47 (part), 53 (part), 57 (part)

Use of NF-kappaB inhibitors for treating allergy.

3. Claims: 2 (part), 5-6, 7-10 (part), 12, 13-20 (part), 46-47 (part), 57 (part)

Use of NF-kappaB inhibitors for inhibiting transplant rejection.

4. Claims: 22-31 (part), 37-47 (part), 49-50 (part), 54 (part), 57 (part)

Use of NF-kappaB inducers for treating infectious diseases.

5. Claims: 22-31 (part), 37-47 (part), 49-50 (part), 51, 54 (part), 57 (part)

Use of NF-kappaB inducers for treating cancer.

6. Claims: 32, 34-36 (part)

In vitro method for inhibiting maturation and activation of dendritic cells.

7. Claims: 33, 34-36 (part)

In vitro method for stimulating maturation and activation of dendritic cells.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No.

PCT/GB 00/04925

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0897009	A	17-02-1999	JP 11155585 A US 6087169 A	15-06-1999 11-07-2000
WO 9942137	A	26-08-1999	AU 2294899 A	06-09-1999
WO 9808955	A	05-03-1998	US 5972674 A AU 726383 B AU 4090497 A EP 0920518 A JP 2001502892 T	26-10-1999 02-11-2000 19-03-1998 09-06-1999 06-03-2001
EP 0894855	A	03-02-1999	US 5952483 A JP 11056376 A	14-09-1999 02-03-1999
WO 9737016	A	09-10-1997	AU 732793 B AU 2175597 A BG 102817 A BR 9708518 A CN 1221449 A CZ 9803183 A EP 0894130 A HU 9902429 A JP 2000507826 T NO 984551 A PL 329218 A SK 136198 A	03-05-2001 22-10-1997 31-05-1999 03-08-1999 30-06-1999 12-05-1999 03-02-1999 28-10-1999 27-06-2000 24-11-1998 15-03-1999 07-05-1999
US 5854043	A	29-12-1998	US 5405941 A US 6074861 A US 5981265 A US 5753446 A AU 697340 B AU 6666394 A CA 2160548 A EP 0694044 A EP 0755406 A FI 954894 A JP 8509128 T NO 954094 A NZ 266067 A PL 311142 A WO 9424159 A WO 9528421 A AU 703070 B AU 8017794 A CA 2186526 A JP 9511906 T	11-04-1995 13-06-2000 09-11-1999 19-05-1998 01-10-1998 08-11-1994 27-10-1994 31-01-1996 29-01-1997 13-10-1995 01-10-1996 13-12-1995 22-09-1997 05-02-1996 27-10-1994 26-10-1995 11-03-1999 10-11-1995 26-10-1995 02-12-1997
WO 9828424	A	02-07-1998	AU 713471 B AU 5618098 A AU 713473 B AU 5718498 A DE 951551 T EP 0951551 A EP 0946725 A ES 2144386 T WO 9828426 A US 6242213 B	02-12-1999 17-07-1998 02-12-1999 17-07-1998 14-09-2000 27-10-1999 06-10-1999 16-06-2000 02-07-1998 05-06-2001

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/04925

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9828424 A		US 6017729 A		25-01-2000
WO 9625666 A	22-08-1996	US 5597898 A CA 2210441 A EP 0811160 A JP 11500312 T US 5849580 A		28-01-1997 22-08-1996 10-12-1997 12-01-1999 15-12-1998
WO 9965449 A	23-12-1999	AU 4690099 A BR 9911152 A EP 1085848 A NO 20006451 A		05-01-2000 06-03-2001 28-03-2001 18-12-2000
WO 9806692 A	19-02-1998	AU 729247 B AU 3913897 A CN 1228080 A CZ 9900439 A EP 0918746 A FI 990180 A HU 9904569 A JP 2000516616 T PL 331605 A SK 17799 A US 6130226 A US 5929117 A		25-01-2001 06-03-1998 08-09-1999 14-07-1999 02-06-1999 08-03-1999 28-05-2000 12-12-2000 02-08-1999 08-11-1999 10-10-2000 27-07-1999
EP 0779361 A	18-06-1997	BR 9606023 A CA 2192738 A CN 1157828 A JP 9216898 A TR 970530 A US 6194175 B		08-09-1998 16-06-1997 27-08-1997 19-08-1997 21-07-1997 27-02-2001
WO 9906009 A	11-02-1999	EP 1017353 A		12-07-2000
WO 9927112 A	03-06-1999	US 5965421 A EP 1034279 A US 6222019 B		12-10-1999 13-09-2000 24-04-2001

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**